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Abstract
Mahmoud S Alghamri Ph.D. Biomedical Sciences Ph.D. Program. Wright State
University, 2016. Novel therapeutic approach for regulating the susceptibility of epithelia
to adenovirus infection.
Human Adenoviruses (AdVs) are etiologic agents for respiratory tract, digestive
tract, heart, and eye infections. Although most AdV infections are self-resolving, some
infections progress to acute respiratory disease with up to 50% mortality, particularly in
immunosuppressed people. Except for vaccines for serotypes, 4 and 7, serotypes that are
prevalent in the military, no vaccines or therapeutics that specifically prevent or treat
AdV infection exist. On the other hand, AdV remains the most common vector system
used in gene therapy clinical trials worldwide and several AdV vectors show promise in
phase III clinical trials.
The majority of AdVs use the coxsackievirus and adenovirus receptor (CAR) as a
primary receptor. We have characterized an alternatively spliced eight-exon containing
isoform (CAREx8) that localizes at the apical surface of epithelial cells and is responsible
for the initiation of apical AdV infection. A cellular scaffold protein named Membrane
Associated Guanylate Kinase, WW and PDZ Domain Containing 1 (MAGI-1) directly
interacts with and alternatively regulates CAREx8 through the C-terminal PDZ-binding
domain. The alternative regulation is due to the interaction with two different domains,
namely PDZ1 and PDZ3, within the same molecule (MAGI-1). I hypothesized that cell
permeable peptides that target the interaction between MAGI-1 PDZ1 domain and
CAREx8 (TAT-PDZ1) would be able to decrease CAREx8 protein levels and prevent AdV
iv

infection. On the other hand, peptides that target the interaction between MAGI-1 PDZ3
domain and CAREx8 (TAT-PDZ3) would be able to increase CAREx8 and enhance AdV
mediated gene therapy. Decoy peptides that target the assigned domain were synthesized
and conjugated to TAT cell permeable peptide to facilitate peptide entry (TAT-PDZ1;
TAT-NET1, TAT-E6) or (TAT-PDZ3; TAT-CAREx8-9c, TAT-ESAM). Peptide entry into
the polarized epithelia was confirmed by mass spectroscopy and fluorescence
microscopy. Treatment with TAT-PDZ1 peptides decreased the cellular levels of CAREx8
and suppressed AdV transduction in MDCK, human airway epithelia (HAE), as well as
epithelia from cotton rats, an animal model of AdV pathogenicity. To determine the
mechanism of peptide action, CAREx8 localization was tracked by immunofluorescence.
Interestingly, TAT-PDZ1 caused nuclear translocation of CAREx8 C-term domain, an
effect that was reversed by ADAM17 inhibitor (TIMP3) and γ-secretase inhibitor (Comp
E), implicating the regulated intramembrane proteolysis (RIP) pathway.
Immunoprecipitation and direct ligand binding assays showed that ADAM17 interacts
specifically with MAGI-1 PDZ2 domain, suggesting that TAT-PDZ1 peptides caused
CAREx8 degradation by enhancing the proximity of the substrate (CAREx8) and enzyme
(ADAM17). Finally, ADAM17 caused CAREx8 extracellular domain (ECD) shedding that
was able to significantly decrease AdV-GFP transduction, indicating a second protective
role against AdV entry by the shed ECD of CAREx8. By contrast, TAT-PDZ3 peptides
increased the levels of CAREx8 and significantly increased AdV entry and transduction in
MDCK, HAE, and cotton rat epithelia. Upon TAT-PDZ3 peptide administration, CAREx8
was localized in vesicular pattern compartments distinct from MAGI-1 and spread
throughout the apical trafficking pathway and at the apical surface of the epithelium.

v

Investigation of the trafficking pathway of CAREx8 using Rabs reveal the possibility of
CAREx8 is residing within the recycling Endosomal-Golgi pathway. Neither TAT-PDZ1
nor TAT-PDZ3 binding peptides altered epithelium formation, as measured by
transepithelial resistance (TER) as well as dextran permeability across the epithelia,
indicating the safety of the peptides on epithelial integrity. Moreover, intranasal
administration of TAT-PDZ3 peptides increased AdV transduction by 300-500% while
TAT-PDZ1 peptides decreased AdV transduction by 80-95% after intranasal
administration in mice demonstrating in vivo activity. Taken together, these results
validate a potential therapeutic approach of TAT-PDZ1 that can be used as a prophylactic
agent to protect susceptible populations from AdV infections or the TAT-PDZ3 which
can enhance adenovirus transduction and offer the potential to increase the efficacy of
adenovirus-mediated gene therapy.
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CHAPTER1: INTRODUCTION
Adenoviruses
Adenovirus (AdV) gained its name due to first being isolated from contaminated
“adenoid” cells where it caused cell deformation (1). At the same time, another group
discovered that it was the agent that was responsible for causing the common cold in
military recruits (2). Soon after, the two microorganisms were recognized as the same
virus (3) and both groups agreed on the common name as “adenovirus” based on the cell
type from which it was first isolated.
The non-enveloped capsid of adenoviruses is approximately 90-100 nanometers
in size and icosahedral in structure. The predominant proteins in the structure of AdV are:
1) The hexon base trimeric structure with more than 240 trimeric structures distributed
equally over the twenty faces of AdV; 2) The penton base proteins distributed evenly to
the 12 vertices of the capsid structure and join it with 3) the fiber knobs that project out of
the icosahedral architecture (Figure 1). The fiber knobs have a crucial role because they
are the first component of the AdV that interact with host cells. The AdV core structure
contains a 35-40 kb double stranded DNA structure, which enables AdV to deliver a
large amount of DNA into the host cell.
Human AdV are classified into more than 57 serotypes, grouped into 7 species
(A-G, Table 1). Most species (all except species B) use the Coxsackie and Adenovirus
receptor (CAR) as their primary receptor. AdV is a serious etiologic human pathogen for
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respiratory tract, digestive tract, heart, and eye infection, and can progress to acute
respiratory distress syndrome (ARDS) and disseminated disease, with up to 50%
mortality rate in ARDS patients (4-7).

2

Figure 1. Model structure of the human adenovirus (AdV).
The penton base protein and hexon are within the core structure that package the
double stranded DNA. The fiber knobs are trimeric protein structure that radiate out
from the core structure and facilitate the AdV binding and entry into the host cell.
Adapted from www.shutterstock.com
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Depending on serotype, AdV can also cause gastroenteritis with prolonged fecal
shedding, or keratoconjunctivitis that can lead to blindness. In highly susceptible,
immunosuppressed populations, such as in the transplant setting, AdV infections can be
lethal. AdV are easily transmitted by airborne droplets from the infected individual to
another, and it can survive in extreme conditions of low humidity and high temperature
(8, 9). Due to its stability and ease of spread, many cases of AdV outbreaks have been
reported (10-13). Epidemic AdV outbreaks occur in closed or crowded communities,
particularly among children and military recruits (4, 14). Such characteristics render AdV
as a highly virulent and opportunistic microorganism and mandate immediate invention
for novel therapeutics. Unfortunately, no therapeutics that specifically treat or prevent
AdV infection are available, and supportive care remains the primary treatment option.

4

Table 1. Classification of Human AdV serotype
Species

Serotype

Site of infection

Receptor (s)

A

12, 18, 31

Gastrointestinal tract

CAR

3, 7, 11, 14, 16, 21,

Respiratory tract,

CD46, CD80,

34, 35, 50,55

Urinary tract

CD86

1, 2, 5, 6, 57

Upper respiratory tract

B

CAR, Sialic
C

acid, CD46
8, 9, 10, 13, 15, 17,
19, 20, 22-30, 32,

Ocular, Gastrointestinal
CAR

D
33, 36-39, 42-49,

tract

51, 53, 54,56
E

4

Respiratory tract

CAR

F

40, 41

Gastrointestinal tract

CAR

G

52
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Current vaccination and therapeutic strategies to control AdV infection
The first AdV vaccination was developed and administered to military recruits in
1971. It successfully reduced the AdV-associated respiratory diseases by 95% (15).
However, the vaccine production was discontinued in 1996 which caused a re-emergence
of AdV infections and associated symptoms among military population (15, 16). The
same vaccine was reinstated in 2011 (17) and resulted in a steep decline in adenovirus
cases from approximately 13,000 per year to a few hundred per year. Interestingly, only
certain adenovirus types (4, 7, and 14) are problems in the military and are distinct from
the types circulating in the civilian population (2, 5, 8, 11, and 21). Therefore, the current
vaccines are relatively military specific.
Over the decades since it was discovered, many attempts have been made to make
additional therapeutics that inhibit AdV infection. Most of these trials have targeted the
viral progeny which develop from the fully mature virus later during the replication stage
of the AdV. One of the most commonly used strategies to block AdV infection is the
inhibition of viral replication. More than 25 agents have been investigated to determine if
they inhibit AdV viral replication. Notably, these agents were initially developed to treat
DNA viruses in general, therefore they are non-specific for AdV infection. They prevent
viral DNA replication by integration into the viral DNA and interfere with viral DNA
elongation. An example (cidofovir) is commercially available anti-DNA viral agent,
however, its selectivity against AdV infection is questionable due to the fact that it works
in the late stage of viral entry and replication. In addition, the side effects developed from
such agent limits its applicability specifically against AdV infection (18-20). Other
antiviral agents that target the DNA replication include the cyclin-dependent kinase
6

(CDK) inhibitors which have been shown to inhibit the spread of AdV in vitro (21). A
major consideration of this group is the wide range of off-target effects, due to the
significant number of substrates available for CDK. Protease inhibitors are another group
of antiviral agents that work by targeting proteases produced by the progeny virions in
infected cells. Recently released simeprevir, the first FDA approved protease inhibitor
against hepatitis C, could give hope for the potential development of anti-AdV protease
inhibitors (22, 23). However, AdV produces many proteases and screening for potent and
selective anti-AdV protease inhibitor may be time consuming process.
As of today, there is no approved or effective treatment for AdV infection. Some
antiviral drugs that non-selectively target DNA viruses are available and anecdotally used
as a last resort against AdV infection due to limited efficacy and wide variety of side
effects (24-26). Inhibition of AdV binding and entry is expected to be the most effective
and prominent strategy to abolish AdV infection. The strategy for inhibition of AdV
binding can be accomplished mainly by targeting the host cell receptor. AdV hijacks
cellular proteins on the surface of host cells to bind and enter, hence, targeting one of the
host cellular proteins may be an efficient way to prevent AdV entry or reduce spread in
the body. There is an increased acceptance of targeting the host cells as an antiviral
strategy. An example is the development of a sialic acid mimetic that would neutralize
and inhibit AdV entry (27). The drug targets some of AdV species C, which use sialic
acid as a co-receptor for binding and entry. The drug is now in phase II clinical trials in
eye drop formulation under the name “APD-209” for prevention and treatment of
conjunctivitis caused by AdV.
Targeting the host cell as potential new anti-AdV or pro-gene therapy strategies
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In contrast to anti-viral agents that target the specific viral pathogen, molecules
that target the host may have promising outcomes for preventing AdV infection. A
hallmark of such strategy is to target host proteins that are being hijacked by the AdV.
This strategy would broaden the biological applications of the agent due to the fact that
many AdVs use CAR as a receptor for binding and entry. Moreover, it can be used
against other types of viruses that potentially use the similar cellular proteins. One
advantage of targeting the host cell is the AdV life cycle depends on many cellular
proteins within host cells. If these cellular proteins are targeted it will make it less likely
for the virion to develop antiviral resistance, in comparison to the other antiviral agents
that target the virions. For example, many microorganisms developed resistance against
their antiviral agents either by releasing proteolytic enzymes to degrade the agent or by
causing mutations in the drug active site. It would not be expected for the virions,
however, to change its main cellular receptor, for example CAR, used for binding and
entry. Therefore, agents that block AdV receptor would be more efficient against AdV
infection with no resistance. Another advantage in targeting the host cell is to broaden the
antiviral activity since many viruses share the same mode of infection toward their host
cells. Finally, it is plausible that the effectiveness of traditional antiviral agents (i.e.
acyclovir) would be enhanced if used in combination with an agent that targets one of the
proteins necessary for viral cycle in the host cells. Such combination would also lower
the required dose of the therapeutic agent which lowers the potential of developing side
effects.
Adenovirus as a vector for gene therapy
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AdV is the most widely used vector for gene therapy (28, 29). It gives high
expression of the gene it carries and it can infect both dividing and quiescent cells.
Besides that, it has the capacity to deliver a large gene load efficiently and the dsDNA
genome can be manipulated through standard molecular methods.
The most common AdV used as vector in gene therapy is AdV5 of which CAR
is the primary receptor, and its transduction efficacy is dependent on CAR expression
(30-32). Experimentally substituting the transmembrane and C-terminus of CAR with a
glycophosphatidylinositol (GPI) tail (GPI-CAR) causes exclusive localization at the
apical membrane of polarized epithelia and increases viral infection (33-35). Therefore,
cells with high CAR expression at the apical membrane are transduced more efficiently
than cells with low CAR levels and targeting the upregulation of apical CAR would be a
good strategy for enhancing AdV mediated gene therapy.
Upon intravenous administration in mice, AdV accumulates mainly in the liver,
followed by spleen, heart, lung, kidney (36). Attempts have been made to change the
distribution of AdV and tissue targeting of the AdV by targeting alternative surface
receptors. One approach was the incorporation of an adaptor within the AdV fiber-knob
structure that would recognize and target a ligand on the cell surface. In such way, the
AdV will travel to the tissue were the receptor for the added ligand is expressed. An
example of that is conjugation of Ad-FAB against a cellular receptor, such as fibroblast
growth factor 2 (EGF2) (37, 38) to target cells with EGF2 receptor expression, or
angiotensin converting enzyme (ACE) to target AdV to the pulmonary endothelium (39).
Other adaptors used include an AdV that was fused with soluble CAR extracellular
domain (sCAR ECD) along with EGF. This adaptation leads to increase AdV
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transduction in EGF positive cells. The disadvantage of the adaptor-AdV fusion is that
the two components were produced separately then fused together by chemical or
physical ways. Such ways could affect the AdV structure or the genetic material that is
being carried. Another disadvantage is that the progeny and nascent virions would lack
these modifications, and therefore will bind to their original cellular receptor CAR, which
may reduce viral transduction.
Another strategy is genetic engineering of ligand within the AdV capsid structure
so that it targets alternative cellular receptors. One of the most common engineered AdV
was by incorporating the RGD motif within AdV structure (40-42). RGD are the 3 amino
acid signals (Arginine, Glycine, Aspartic acid) that interact with surface integrins. AdVRGD, Ad5.SSTR/TK.RGD is the most promising example which has passed phase I
clinical trials (43) and has proven to have high efficacy of gene transduction in vitro.
In spite of the successful clinical trials using AdV as a vector, a major setback
occurred in 1999 when 18-years old Jesse Gelsinger died after administration of a large
inoculum (3.8 1013 particles) of AdV to restore ornithine transcarbamylase, an enzyme
responsible for amino acid de-amination and ammonia metabolism in the body. Gelsinger
died due to multi-organ failure and disseminated intravenous coagulation (44).
Interestingly, a female patient who received a similar dose did not experience any such
adverse effects (44). Although the administered AdV was replication deficient, high
inoculums of AdV can still cause adverse effects. Therefore, molecules that increase the
efficacy of AdV transduction would be able to overcome this drawback by allowing the
administration of a low AdV inoculum.
Coxsackie and Adenovirus Receptor (CAR)
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CXADR, the gene for CAR, was cloned and characterized in 1997 by three
different groups (30-32). It is located on chromosome 21q11.1 and is composed of eight
exons (45) spread over 54,000 nucleotides. The most abundant form of CAR protein is
composed of one polypeptide chain (365 amino acids) which belongs to class I
transmembrane protein (Figure 2). Its protein structure is composed of four domains, two
of them form the extracellular D1 and D2 (214 aa), transmembrane domain (23 aa), and
107 aa intracellular domains (30). The D1 extracellular domain forms homodimers and,
thus, it is responsible for the cell adhesion function of CAR (46-49). The same aa within
the D1 loop that mediate CAR-CAR adhesion also compose the binding site for AdV
fiber knob. Neither the transmembrane domain nor the intracellular domain are important
for viral binding and entry since replacement of these domains with a GPI-linked tail is
sufficient to maintain equivalent infection (33). The cytoplasmic domain does play an
important role in regulation and stability of the cellular levels of CAR. CAR is prone to
many post translational modifications including, 1) phosphorylation at many tyrosine
(Y269, Y294, Y313, and Y318), threonine (T29), or serine (S293, S323, and S332)
residues (50) , 2) palmitoylation on cysteine C259, C260 (51), and 3) ubiquitination (52).
Of particular importance, the extreme cytoplasmic domain of CAR encodes a PDZ
binding domain motif -GSIV (or –ITTV in the 8 exon isoform of CAR), a motif that
enables CAR to interact with PDZ domain containing proteins. The significance of CAR
PDZ domain interactions is discussed in detail below (CAR interactions with PDZ
domains containing protein).
CAR expression
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CAR is expressed in most organs, but is predominantly expressed in the
developing heart, airway epithelium, and brain (31, 53). In the heart, CAR levels change
dramatically during embryonic development. During the early embryonic stage, CAR
levels are high in the myocardium; this high concentration drops progressively as the
heart matures (31, 54). Deletion of CAR leads to the formation of lesions and cardiac
hemorrhaging (54, 55), ventricular hypertrophy, and defects in the sinoatrial valve (56).
Asher et al. and others showed that in CAR KO mice, all embryos died 11-14.5 days post
conception due to myocardial dysfunction (54-56). This indicates that CAR is essential
for normal cardiac function during the early stages of embryonic development and
suggests that CAR is a “pathfinder” receptor that mediates cardiomyocyte junction
formation and integrity (57).
CAR expression levels remain relatively high in the epithelial cells of several
organs such as lung, liver, and intestine in adult organisms (58). It was predominantly
expressed in cell layers lining body cavities including polarized epithelia (59). In welldifferentiated airway epithelia the eight exon isoform (CAREx8) is localized at the apical
surface (45), where it can function as an anchor site for neutrophil binding on the
epithelial apical surface (60). CAR was also found to localize at the apical membrane of
retinal epithelial cells (61).
Splicing of CAR
Most adenoviruses and group B coxsackieviruses invade the human epithelium
using CAR as a primary receptor (30, 31, 62). CXADR can express four isoforms of
CAR, only two of them are transmembrane isoforms, namely CAR1 (CAREx7) and
hCAR2 (CAREx8), which differ in their intracellular domain (ICD). The two isoforms are
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structurally similar except for the cytoplasmic extreme C-terminal domain; 13 aa in
CAREx7 and 26 aa in CAREx8 (Figure 2). Another crucial difference between the two
isoforms is their localization in polarized cells. Whereas CAREx7 is buried within the
basolateral junction adhesion complex of the human epithelium, and therefore, it is not
directly accessible to the incoming airborne viruses, CAREx8 is localized at the apical and
sub-apical air-exposed surface of human epithelial cells and provides a direct binding site
for the incoming virus (45, 63, 64). Viral receptor isoform-specific localization and
function has also been described for the poliovirus receptor. The poliovirus receptor
(hPVR/CD155) has two transmembrane isoforms with differential localization in
polarized epithelia (65). While hPVR resides on the basolateral surface, hPVR appears
on the apical surface where it can mediate apical poliovirus entry. The regulation of
apical versus basolateral localization for hPVR is also currently unknown but may rely on
overlapping mechanisms with the CAR isoforms.
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Figure 2. Alternative Coxsackievirus and adenovirus receptor (CAR) spliceforms.
The two isoforms are only different in the extreme C-terminal domain with 26 aa in
CAREx7 replaced with 13 aa in CAREx8. Adapted from (45).
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CAREx8 mediates adenovirus infection of primary airway epithelia
The first step for initiation of AdV infection is binding to a cell surface receptor.
Except for group B AdV which use CD46 for binding and entry (66-69), most AdV
serotypes use CAR as a common receptor for binding and entry into cells (70, 71).
Following binding, AdV requires a secondary interaction with integrins (72). Integrins
are heterodimeric cell surface transmembrane proteins known to be involved in cell
adhesion, migration, growth, and differentiation. Integrins ανβ1, ανβ3, and ανβ5 are the best
described AdV co-receptors and are known to enhance the AdV entry step into host cells
(72, 73). They promote AdV entry by binding to the RGD motif found within the AdV
penton base which facilitate virus entry. AdV then internalized via clathrin-mediated
endocytosis (74). The signaling pathway that causes dynamin and clathrin triskelions to
be recruited to the AdV binding site and the surrounding milieu is currently unknown.
However, endocytosis of the clathrin-coated vesicle is followed by stepwise dismantling
of the virion fiber knobs and endosomal escape of virion to the cytoplasm by pH
dependent process (75, 76). Adenovirus has also been shown to enter by non-clathrin
mediated endocytosis pathways including macro- and micropinocytosis (77, 78). Once in
the cytoplasm, the virion capsid interacts with microtubule motor proteins that lead to the
nucleus. Additional uncoating of the capsid occurs at the nuclear pore which then allows
transfer of viral DNA into the nucleus (Figure 3) (79, 80).
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Figure 3. The process of AdV entry and infection.
AdV binds the cell surface receptor CAR. Integrins function as co-receptor for AdV to
facilitate its entry. AdV is endocytosed by clathrin-mediated endocytosis followed by
viral escape by endosomal acidification which causes stepwise dismantling of the
virion structure. The virion travels along microtubules and binds to nuclear pore
complex. The virion then ejects its DNA into the nucleus which triggers viral
replication. Adapted from Coughlan et al., 2010 (81).
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The pulmonary epithelium is a highly characterized system lining the respiratory
tract. It exposes a vast surface area to the ambient air, thereby allowing efficient gas
exchange of oxygen and the metabolic waste product carbon dioxide. It is also the first
line of defense for an airborne microorganism to infect the respiratory system. The
pulmonary epithelium is characterized by its ability to polarize and form tight junctions
that seal the basolateral surface of the respiratory tract from pathogenic microorganisms
on the apical surface. For a long time, the dominant isoform, CAREx7, was believed to be
the only primary epithelial AdV receptor and viral access to basolateral CAREx7 required
a transient or sustained break in the tight junction (77). The discovery of CAREx8 causes
paradigm shift from the traditional knowledge about AdV infection and gives incentives
to researchers to look for a strategy to target the apically localized CAREx8 isoform.
We have discovered that the eight-exon CAR isoform (CAREx8) localizes to the
apical membrane of polarized primary human airway epithelia and mediates apical AdV
entry (Figure 4) (45, 63, 64). CAREx8 is the AdV receptor at the apical surface of
polarized epithelia and the susceptibility of an epithelium to adenoviral infection can be
directly impacted by either increasing or decreasing CAREx8 expression (Figure 5). This
discovery has opened the doors toward investigations and discovery of new therapeutic
strategies aimed to downregulate CAREx8 for the purpose of inhibition of AdV infection,
or to upregulate CAREx8 in order to enhance AdV gene therapy in target tissues.
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Figure 4. CAREx7 and CAREx8 localize and behave distinctly in well-differentiated
primary human airway epithelia (HAE).
(A) CAREx7 (green) overlaps (yellow) and is basolateral to the tight junction protein
ZO-1 (red). (B) CAREx8 (green) localizes to an apical compartment and is distinct from
ZO-1 (red). The arrow indicates CAREx8-specific staining above the ZO-1 delineated
tight junction. (C) Background staining with pre-immune rabbit serum (green) and ZO1 (red). Over-expression results in (D) CAREx7 localization primarily at the basolateral
junctions and E) CAREx8 localization diffusely and at the apical surface of HAE. (F)
Augmenting CAREx8 expression significantly increases apical adenovirus, encoding the
gene for β-Galactosidase (Adβ-Gal), transduction over GFP or CAREx7 expressing
epithelia *p<0.01. Dotted line represents support membrane; AP, Apical surface; BL,
Basolateral surface. Confocal microscopy (60x oil immersion). Adapted from (45).
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Figure 5. Accessibility of CAR to adenovirus entering from the lumen of the
airway.
(A) CAREx7 localizes beneath the tight junctions at the basolateral surface of polarized
epithelia and is not accessible to incoming AdV. (B) CAREx8 localizes at the apical
surface and in a recycling endosome. Apical CAREx8 allows AdV to bind, internalize,
and infect cells from the airway lumen.
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PDZ interactions
PDZ domains were first identified in three proteins: postsynaptic density protein
(PSD95) (82), its Drosophila homologue discs large tumor suppressor (DlgA) gene
product (83) and zonula occludens-1 (ZO-1) (84), a tight-junction protein. PDZ domain
containing proteins are a huge class of “scaffolding proteins” that can simultaneously
interact with several proteins and are involved in screening and sorting of many
intracellular and transmembrane proteins. They play an important role in the trafficking
and stability of many proteins, including apically localized proteins such as CFTR (85).
The membrane-associated guanylate kinases (MAGUKs) are a family of scaffolding
proteins responsible for organizing many groups of proteins at the cell-cell junctions (86,
87). MAGUKs are characterized by having a SH3 domain, a guanylate kinase domain
(GK), WW domains, and multiple PDZ domains (Figure 6). Most MAGUKs family
members localize at the cell junction and this localization occurs in the absence of the
GK domains as well as the extended carboxyl terminus (88).
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Figure 6. Examples of members of the membrane associated guanylyl kinases
(MAGUK) family.
Most MAGUKs share a SH3 domain (yellow), a guanylate kinase domain (red) and
PDZ domains (blue). Modified from (89)
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Individual PDZ domains are composed of 80-100 amino acids that have a
structurally well-defined interaction ‘pocket’ that interacts with PDZ binding domains
(90). The domains can recognize short C-terminal sequences in target proteins, called
PDZ binding domains that contain one of four classes of consensus sequences, type I
(S/T-x-Ф–COOH), type II (Ф-x-Ф–COOH), type III (-x-Ф–COOH) and type IV (D-xV–COOH) where (X) is any amino acid, (Φ) is hydrophobic aa (V, I, L, A, G, W, C, M,
F), and (Ψ) is basic aa (H, R, K) (90-93). We have shown that the PDZ domain
containing cellular protein, MAGI-1 (member of MAGUKs family), is a master switch
for CAREx8 protein levels and apical AdV infection of polarized cells (63).
The function of each PDZ domain containing protein is diverse. Many of them
such as LNX1 (94), MARCH2 (95), and PDLIM2 (96) were shown to contain a ubiquitin
ligase in their structure. Others, such as Crumbs, Scribble, and Par are suggested to be
responsible for establishing apical and basolateral polarity in epithelia cells (97). The
majority of them, MUPP1, PATJ, MAGI-1, and ZO-2, lack a catalytic domain and
instead form a multiple protein-protein interaction module with tight junction molecules.
Alternatively, they may be responsible for proper trafficking and subcellular localization
of many receptors and ion channels such as such as the β-adrenergic receptor (98),
potassium channels (99), sodium channels (100), and NMDA receptors (101).
CAR interactions with PDZ domains containing protein
The cellular stability of CAREx8 protein level is regulated by a PDZ domain
containing protein called MAGI-1 (Membrane Associated Guanylate Kinase, WW and
PDZ Domain Containing 1). MAGI-1, is a master switch for CAREx8 protein levels and
apical AdV infection of polarized cells (Figure 7) (63). We found that the effect of
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MAGI-1 on CAREx8 is mediated by the PDZ binding domain of CAREx8 located at its
extreme C-terminus domain. Interestingly, two PDZ domains within MAGI-1 recognizes
the C-terminal domain of CAREx8, namely PDZ1 and PDZ3. It is speculated that the
concentration of CAR at the membrane is regulated mainly by PDZ domain containing
proteins. Indeed, CAR has been shown to interact with many PDZ domain containing
proteins located at the interior side of the membrane including MUPP-1 (102), MAGI-1b,
PICK1 and PSD-95 (103), LNX and LNX-2 (104, 105), and ZO-1 (47). These
interactions are not only relevant for regulating the concentration of CAR via interactions
with scaffolding proteins such as MAGI-1b (63), but also for the proper trafficking of ion
channel proteins such as, acid sensing ion channel 3 (ASIC3) (106).
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Figure 7. MAGI-1 PDZ3 decreases viral infection, while PDZ1 inhibits MAGI-1mediated CAREx8 suppression to allow adenovirus infection.
CAR-deficient CHO-K1 cells were (A) single, or (B) double transfected with CAREx8,
full length MAGI-1 (black bars), PDZ1 domain (dotted bars), or PDZ3 domain (white
bars), and balanced with empty pcDNA3.1 plasmid (gray bars), followed by AdV-βGal (MOI 100) transduction. Adapted from (63).
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MAGI-1, an easy viral target
Many viral proteins contain PDZ binding domains and subvert the activity of
cellular PDZ domain containing proteins to enhance the viral lifecycle and/or increase the
virulence of the virus (107-109). Of particular importance here, MAGI-1 interacts with
over 40 cellular and viral proteins (110). One of these proteins is the human papilloma
virus (HPV) E6 protein which binds to and stimulates MAGI-1 degradation to disrupt
tight junctions and promote oncogenesis (108). MAGI family proteins exhibit the
strongest binding to and most efficient degradation by E6 via proteasome-mediated
degradation (108, 111-113). Recent findings suggest that HPV E6-mediated degradation
of MAGI-1 promotes tight junction disruption in epithelial cells (114). Therefore, many
viral proteins may have been developed to hijack the host cell function in order to
promote their virulence and enhance their replication.
Targeting protein interactions by cell permeable peptides
Rapid transduction of proteins into cells can be facilitated by cell permeable peptides
(CPP; also called cell penetrating peptides) (115-117). The 11-amino acid minimal
transduction domain of HIV-1 TAT (residues 47-57) can facilitate protein entry into a wide
variety of cells both in vitro and in vivo (118, 119). Many other CPPs have been described
from octa-arginine to AdV dodecahedrons (115, 120, 121). TAT-CPPs are in clinical trials
and clinically approved protein-based therapies are available (e.g. surfactant proteins,
DNase) (122-124). Interactions with the fifth MAGI-1 PDZ domain (PDZ5) has been
targeted in MDCK cells using CPP and caused the disruption of the MAGI-1 interaction
with β-catenin, an important cellular cell junction and signaling protein (125). Moreover,
CPP that target PDZ domain interactions with the neuronal scaffolding protein PSD-95
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protect against neuropathic pain and ischemic brain damage in murine models (126, 127).
Interestingly, the PDZ binding domain motif of CFTR is required for its degradation (95)
and modified cell permeable peptide has been used recently to rescue CFTR activity from
its PDZ domain containing protein that mediates CFTR degradation (128). Moreover,
disturbing the PDZ interactions has been used to protect against long term potentiation and
depression (129), Huntington’s disease (130, 131), cystic fibrosis (132), and cancer (133).
Therefore, targeting PDZ dependent interactions are potential future therapeutics for many
diseases and disorders (90).
Model for altering CAR trafficking and degradation in polarized cells
CAREx8 can interact with two MAGI-1 PDZ domains, PDZ1 and PDZ3, which
regulate CAREx8 levels in opposing ways. Results showed that the MAGI-1 PDZ3
domain is responsible for CAREx8 degradation. However, when CAREx8 interacts with the
MAGI-1 PDZ1 domain, CAREx8 was rescued from MAGI-1 induced CAREx8 degradation
(Figure 8). The mechanisms behind how these domains have opposing activities are
currently unknown. Understanding these mechanisms will have significant clinical
implications for prevention of wild-type viral infection or improving AdV-mediated gene
therapy and is the focus of this thesis.
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Figure 8. Model of MAGI-1 mediated CAREx8 regulation.
(A) MAGI-1 PDZ3 domain mediates CAREx8 degradation which suppresses AdV
entry. (B) MAGI-1 PDZ1 domain rescues CAREx8 and promotes AdV entry into the
epithelial cells.
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The interaction of CAREx8 with MAGI-1 requires the CAREx8 PDZ binding
domain (45). Previous data showed that deletion of the CAREx8 C-terminal ITVV PDZ
binding domain sequence allows CAREx8 protein expression at cell junctions, where no
co-localization with MAGI-1 is observed (45). However, the PDZ binding domain is not
sufficient and the degradation phenotype requires the upstream CAREx8-specific
sequence. Interestingly, switching the CAREx7 GSIV sequence with the CAREx8 ITVV
sequence does not switch the degradation phenotype between the two isoforms (45).
These data show that the ITVV sequence interacts with MAGI-1 but that the last 9 amino
acids of the CAREx8 C-terminal domain sequence play an important role in degradation.
We hypothesize that this reflects a CAREx8 specific interaction with MAGI-1 directly and
that such interactions can be controlled by using specific cell permeable peptides to
interrupt the MAGI-1 PDZ domain interactions with CAREx8 (Figure 9). Notably, other
proteins may also modulate this direct interaction between CAREx8 and MAGI-1.
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Figure 9. Model of TAT-peptide-mediated MAGI-1 PDZ domain blockers.
(A) It is hypothesized that TAT-PDZ1 binding peptides (TAT-E6 and TAT-NET1)
bind to and block the PDZ1 domain increasing CAREx8 - PDZ3 domain interactions
that promote CAREx8 degradation and suppress AdV entry. (B) It is hypothesized that
TAT-PDZ3 binding peptides (TAT-ESAM and TAT-CAREx8-9C) bind to and block the
PDZ3 domain increasing CAREx8 – PDZ1 domain interactions that rescue CAREx8 from
degradation and increase AdV entry into the epithelial cells. Note that it is expected
that TAT-CAREx8-9C will bind to both PDZ1 and PDZ3 but will function like a PDZ3
blocker due to its high affinity binding to PDZ3 domain.
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Hypothesis
My central hypothesis is that decoy peptides that interrupt one or both of the
interactions between MAGI-1 and CAREx8 can destabilize apical CAREx8 protein to
abrogate adenoviral entry or upregulate apical CAREx8 protein to enhance AdV gene
therapy.
Specific aims
Specific aim 1: To determine the cellular mechanism of “attenuator” cell permeable
peptides that bind to the endogenous MAGI-1-PDZ1 domain and their effect on AdV
infection.
Specific aim 2: To determine the cellular mechanism of “potentiator” cell permeable
peptides that bind to the endogenous MAGI-1-PDZ3 domain and their effect on AdV
infection.
Specific aim 3: To determine whether cell permeable peptides that bind to the
endogenous MAGI-1-PDZ1 or MAGI-1-PDZ3 domain would change AdV infection in
vivo.
Model illustrative diagram of the hypothesis and specific aims is shown in Figure 10.
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Figure 10. Model illustration of the hypotheses and specific aims.
(A) MAGI-1 regulates the protein level of CAREx8 by two of its PDZ domains. (B)
TAT-PDZ1 peptides bind to and block the PDZ1 domain forcing CAREx8 - PDZ3
domain interactions that promote CAREx8 degradation and suppress AdV entry (Aim 1).
(C) TAT-PDZ3 peptides bind to and block the PDZ3 domain forcing CAREx8 – PDZ1
domain interactions that rescue CAREx8 from degradation and increase AdV entry into
the epithelial cells (Aim 2).

31

Table 2. MAGI-1 PDZ domain interacting partners
Protein
(Gene)

Amino acid sequence

MAGI-1
PDZ domain

Ref.

α-actinin 4 (ACTN4)

STALYGESDL

5

(134)

BAI-1

QDIIDLQTEV

3, 4

(135)

β-Catenin (CTNNB1)

NQLAWFDTDL

5

(136)

Cadherin 23 (Cdh23)

METPLEITEL

4

(137)

CAREx8

PYKTDGITVV

1, 3

(63)

Carom (FCHSD2)

KIEDVEITLV

4, 5

(138)

ESAM

PAQSQAGSLV

3

(139)

JAM4

PQKVRNVTLV

1, 4

(140)

Kir4.1

SALSVRISNV

5

(141)

Megalin (LRP2)

ANLVKEDSDV

5

(142)

Nephrin

LPFELRGHLV

2, 3

(143)

NET1

QSGGKKKETLV

1

(144)

PTEN

DQHTQITKV

2

(125)

TRIP6

ELSATVTTDC

5

(145)

Beta1AR (ADRB1)

PGFASESKV

1

(146)

RapGEP

EDEDEQVSAV

0, 1

(147)

3

(148)

Slo1 (KCNMA1)

KQKYVQEERL
PPIREVEDEC

HPV E6

SRTRRETQL

1

(112)

Ad9 E4Orf1

FPSVKIATLV

1, 3

(108)

Influenza A virus NS1

KMARTARSKV

1, 5

(149)

CAREx7

PAQSKDGSIV

3

(150)
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CHAPTER 2: Materials and Methods
Materials
Cell Lines
Epithelial and non-epithelial cell lines were used for various experiments (Table
3). 3T3 J2 cell line was obtained from Howard Green, MD (Harvard University). Primary
HAE (Donor 2) and the HEK 293 cell line were obtained from the University of Iowa
Cell Culture
Core. The remaining cell lines were purchased from ATCC, Virginia. All cell lines were
stored in liquid nitrogen in the Department of Biological Sciences at Wright State
University, Dayton OH.
Culture Media
Cells were cultured in appropriate sterile culture medium (GibcoTM Invitrogen
Corporation, Grand Island, NY) supplemented with 10% fetal bovine serum (except
MDCK, supplemented with 5% FBS) immediately after removing the cells from liquid
nitrogen. After stimulation of growth, the culture medium was further substituted with a
final medium-serum mix containing penicillin and streptomycin antibiotics. The
powdered culture medium, containing L-glutamine and 25 mM HEPES buffer, was
dissolved in distilled deionized water (ddH2O) from a Nanopure Millipore Water System.
All culture media were supplemented with 2.024 g/L sodium bicarbonate. The
solution was adjusted to pH 7.0 to 7.1 with 1 N HCl dropwise. The culture media
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solutions were sterilized through a 0.2 μm-pore cellulose nitrate Nalgene vacuum
filtration apparatus.
Sterile media were supplemented with 0.5% penicillin/streptomycin and the appropriate
heat inactivated fetal bovine serum by appropriate volume percentage. The final culture
media was stored in 500 ml Pyrex bottles and kept at 4ºC.
Competent Cells
BL21 derivative competent cells (Rosetta) were used for transformation and
protein purification experiments according to their unique properties (see protein
purification section). Competent E. coli DH5 alpha were used to store the transformed
plasmid expression protein in glycerol stock (-80ºC).
TAT-PDZ Peptides
TAT-PDZ peptides used in this study and their binding affinities are listed in Table 4.
Antibodies
The antibodies used in this study are listed in Table 5.
Primers
The list of primers used in this study is shown in Table 6.
SiRNA
The list of siRNA used in this study and their target sequences is shown in Table 7.
Inhibitors
The list of inhibitors used in this study is shown in Table 8.
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Table 3. List of cell lines used in the study
Cell Name

Cell Type

ATCC No

Media

Cotton rats

PTA-3930

F-media
DMEM (low
glucose)
DMEM (low
glucose)

HeLa

Rat Lung Epithelia
Chinese Hamster
Ovary
Transformed
Monkey Kidney
Human Embryonic
Kidney
Embryonic Mouse
Fibroblast
Madin Darby
Canine Kidney
Cervix Epithelia

HAE

Donor 2

CHO-K1
COS-7
HEK 293
3T3-J2
MDCK

CCL-61
CRL-1651

Seeding
(0.5 ml)
2 x 105
1 x 105
1 x 105

DMEM

1 x 105

DMEM

1 x 105

CCL-34

EMEM

4 x 105

30-2003

EMEM
F-media/
differentiation
media

2 x 105
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2 x 105

Table 4. TAT-PDZ peptides used in this study and their binding affinities
Peptide name

Kd (nM),

Kd (nM),

Kd (nM),

PDZ1

PDZ2

PDZ3

sequence

TAT-CAREx8-9c

YKTDGITVV

23± 10

N.I

4±2

TAT- CAREx8- AA-

YKTDGIAVA

113± 28

N.I

71± 19

TAT-NET1

SRTRRETQL

28 ± 11

N.I

N.I

TAT-E6

GGKKKETLV

15 ± 4

N.I

N.I

TAT-Scramble

QGDITVKVT

N.I

N.I

N.I

TAT-ESAM

AQSQAGSLV

N.I

N.I

17 ± 5

TAT-ADAM17-9c

RVDSKETEC

N.I

35 ± 8

N.I

9c

N.I, No detectable interactions
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Table 5. Antibodies used in the study
Table 2. Antibodies used in the study
Antibody
Vendor
Cat #
Mouse primary antibody
Actin
Ambion
AM4302
DAPI
Vectashield
H-1200
Fisher
MA1Flag
Scientific
91878
GST
GenScript
A00865
Novus
MAGI-1
9223-M03
Biologicals
Myc
Cell Signaling 2276S
ZO-1 (dog)
Invitrogen
33-9100
ZO-1 (human)
BD Bioscience 610967
Rat Primary Antibody
Rab 4,5,7,9,11
Cell Signaling 9385S
Flag
Cell Signaling 14793S
University of
CAR (1605)
Iowa
University of
CAREx8 (5678)
Iowa
GFP
Invitrogen
A11122
MAGI-1
Novus
Myc
Cell Signaling 2278S
University of
PPRP-YY1
AB3792
Iowa
ZO-1
Invitrogen
61-7300
Thermo
ADAM17
PA5-19872
Scientific
Thermo
ADAM17
RB1660P0
Scientific
Donkey IgG HRP Labeled Secondary Antibody
Jackson
Mouse
Immuno
715035150
Research
Jackson
Rabbit
Immuno
715035150
Research
Goat IgG Alexa Fluor Labeled Secondary Antibody
Mouse A488
Invitrogen
a10667
Mouse A568
Invitrogen
a11004
Rabbit A488
Invitrogen
a11008
Rabbit A568
Invitrogen
a11036
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Dilution for WB/IF
1:2000-1:3000
1:20000
1:1000
1:1000
1:500
1:1000
1:200
1:200
1:500-1:1000
1:1000
1:1000-1:2000
1:200
1:1000-1:2000
1:200
1:1000
1:200
1:200
0.5µg/ml
5µg/ml

1:10000

1:10000

1:1000
1:1000
1:1000
1:1000

Table 6. List of primers and their sequence
Primer Set
AdV Hexon specific
primer
CAREx8
GAPDH
Actin
CAREx8 (stable MDCKCAREx8)
ADAM17

Forward Primer 5' → 3'
ACGCCTCGGAGTACCT
GAG
TCGGCAGTAATCATTC
ATCCCTGG
CACCCTGTTGCTGTAG
CCAAA
AAGATCTGGCACCACA
CCTTCTAC
GTCCCTCCTTCAAATA
AAGCTG
GGGGCCCCTGGGATCC
ATGAGGCAGTCTCTCC
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Reverse Primer 3' → 5'
GTGGGGTTTCTGAACTT
GT
ACTGTAATTCCATCAGT
CTTGTAAGGG
CAACAGCGACACCCAC
TCCT
ATCTGGGTCATCTTCTC
ACGGTTG
ACTGTAATTCCATCAGT
CTTGTAAGGG
GTCGACCCGGGAATTC
GGCTAGCACTCTGTCTC

Table 7. List of siRNA used in the study

siRNA

Vendor

Cat #

Target Sequence

ADAM17

Dharmacon

A-003453-13

GGAUGUAAUUGAACGAU
UU
CCAAGAUUUUGAUAUGG
ADAM17

Dharmacon

A-003453-14
GA
GCAUCAAUACUUUUGGA

ADAM17

Dharmacon

A-003453-15
AA
GGUCUAUUUCUAGUUAU

ADAM17

Dharmacon

A-003453-16
UA
UGGUUUACAUGUCGACU

ON-TARGET plus

Dharmacon

D-001810-01-05
AA

MAGI-1 (A)

Invitrogen

1299001
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Exon 21,22,23 SMARTpool

Table 8. Inhibitors used in this study
Inhibitor

Vendor

Cat #

MG-132

Fisher Scientific

AP81-5-15A

TAPI-1

Calbiochem

579051

TIMP3

R & D systems

973-TM

Compound E

Calbiochem

565790

Cyclohexamide

Sigma-Aldrich

01810
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Methods
Cell culture maintenance
Cell culture techniques were performed under a laminar flow hood using aseptic
techniques. Cell cultures were stored and grown in 25 or 75 cm2 tissue culture flasks
within a humidified incubator at 37ºC and 5% CO2 concentration. The media-serum mix
was changed in the flasks based upon a pH change from 7.1 to about 6.0, as indicated by
a color change of the media from pink to yellow. As cells began to divide and reach
approximately 80% confluency, the cell cultures were divided into new flasks using a
cells to media ratio of between 1:5 and 1:20 after removing attached cells with 0.25%
Trypsin-EDTA (Mediatech, Inc., Manassas, VA). All flasks were supplied with new
media-serum mix to a final volume of 5 ml in a 25 cm2 tissue culture flask and 10 ml in a
75 cm2 tissue culture flask. Cell viability was verified before each experimental set using
the trypan blue exclusion test (151). Dead cells appeared blue, as their cell membranes
are permeable to the dye upon death. Cell viability above 80% was considered suitable
for experiments.
Determination of cell concentration (hemocytometer)
The technique reported was used during cell seeding before transfection and
adenovirus infection. Adherent monolayers of cells were trypsinized from 1-2 flasks and
combined in a 50 ml centrifuge tube. The tube was centrifuged at 150 rcf for 5 min at
4ºC. The supernatant was aspirated and the cells resuspended in 1 ml culture medium and
mixed gently by pipetting up and down. A clean coverslip was centered on a
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hemocytometer between the outside railings over the two counting grids. A drop (10 µl)
of well-mixed cell suspension was placed at each notch. The drop was added once to
ensure even distribution of cells. Cells were counted with a push button counter using
400 X total magnification. Cells were counted in the four corner squares (1 mm X 1 mm)
of the cytometer. These squares were 1/400 mm2. The average value of the total cells
counted in the 4 squares was multiplied by 104 to determine the number of cells per
milliliter. The volume of the mixture was adjusted by dilution with culture media to an
appropriate concentration, depending on the particular assay.
Peptide preparation and treatment
TAT-Peptides were synthesized by the Genescript peptide synthesis core
(Genescript, MO) as a white powder. A list of all synthesized peptides and their binding
affinities is shown in Table 4. A stock solution of approximately 1 mM of each peptide
was prepared and dissolved in PBS. For peptide treatment, cells were washed with PBS 3
times and treated with small volume (50µl of 1 - 100 µM dose) of peptide directly into
cells. Serum free Opti-MEM was added and incubated for 1 hr or as described in the text.
Media was changed to Opti-MEM containing fetal bovine serum for 4-5 hrs. After that
cells were washed again and either fresh media added or lysed with lysis buffer
containing protease inhibitor depending on the experiment. Unless otherwise indicated, in
conditions where CAREx8 was induced using inducible MDCK epithelial cells, 100 µM of
TAT-peptides were used in treatment for a period of 4-5 hrs.
Matrix Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS)
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Polarized MDCK cells (≈ 1*106) were incubated for 60 min at 37°C with 1 or 50
µmol/l TAT-CAREx8-9c peptide in starvation media containing (Opti-MEM with earle’s
salt). After 1hr incubation, cells were washed with PBS, and lysed with lysis buffer
containing 2 mmol/l PMSF and 0.1% Trifluoroacetic acid (TFA). Lysate was washed
with 50 mM sodium acetate buffer containing 150 mM Nacl. Cells were centrifuged at
135,000 rpm. Equal amounts of protein lysate were transferred into new tubes. Peptides
were purified using C18 Ziptips (Millipore, Billerica, MA) according to a previously
published procedure (152). Briefly, the Ziptip was activated with 100% acetonitrile,
followed by washing 3x with 0.1% TFA. After that, the sample was loaded into column
by repeated pipetting 20-30 times. Column was washed again 3 times with 0.1% TFA.
Finally, peptide was eluted with 95% acetonitrile containing 0.3% TFA. Elution was
spotted on a Brucker protein plate chip containing (alpha cyano-4- hydroxycinnamic acid
in 70% acetonitrile, 10% acetone, 0.3% TFA).
Mass spectra were obtained using a Bruker Autoflex III smart beam MALDI
TOF/TOF instrument. A total of 7,000 laser shots were acquired randomly for each spot
at a laser frequency of 100 Hz. The mass spectrum was accumulated and normalized to
the peak m/z in each spectrum.
Fluorescently-labelled peptide internalization
TAT-CAREx8-9c peptide was synthesized (genescript, NJ) and tagged with
TAMRA (red fluorescence). Cells were treated with the fluorescent peptide at different
time points after which they were washed with PBS, fixed with 1% PFA in methanol and
cover slipped with DAPI solution. Images were taken by confocal microscope at 60X oil
immersion magnification.
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Testing for expression of proteins in E. coli
Confirmed clones of MAGI-1 PDZ domains (pHH2 plasmids) were transformed
into E.coli using the Rosetta strain of competent cells (EMD chemicals, Gibbstown, NJ).
Rosetta competent cells are BL21 derivatives that supply tRNAs for AGG, AGA, AUA,
CUA, CCC, GGA codons on a chloramphenicol-resistant plasmid and are therefore
capable of expressing eukaryotic proteins that contain codons rarely used by E. coli.
Transformation was done by adding 100 ng pHH2 plasmids into 10 µL competent cells in
a 2.0 ml centrifuge tube and kept on ice for 30 min. The tube was heat shocked for 45 sec
at 42°C and kept back on ice for 2 min. 250 µL SOC medium was added to the cells and
the tube incubated for 1 hr at 37°C with shaking at 200 rpm. Each vial of transformed
cells was then spread on ampicillin (100 μg/ml) and chloramphenicol (10 μg/ml)
containing LB agar plates (20% and 80%) and incubated overnight at 37°C. The next
day, 3 - 9 colonies of each plasmid were grown overnight as 1 colony per 5 ml of LB
broth containing ampicillin (100 μg/ml) and chloramphenicol (10 μg/ml). Next day, 500
µL of each overnight culture was subcultured into three 5 ml of LB (Amp+, Chl+) broth
(a total of 15 ml culture/colony) and grown until an OD600 od 0.6-0.8 was contained, after
which 1 ml of culture was transferred from each sample into another tube and stored at 20°C as the zero hour non-induced sample. 10 µL of 100 mM IPTG was added to each
remaining 2 ml culture to induce protein expression and continued incubation at 37°C. 1
ml samples were taken at 1, 2, 4, 6, 8, 12, 24 hrs. All samples were centrifuged at 9,500
rpm, 4°C for 10 min. Each pellet was resuspended in 100 µL PBS and sonicated with
pulses to completely lyse the cells. The lysate was again centrifuged after which the
supernatant was transferred into fresh tubes on ice. Protein samples were mixed with 2X
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SDS denaturing buffer and incubated at 75°C for 5-10 min with shaking at 300 rpm.
Then, 35 μl of protein from each sample was subjected to SDS-PAGE and the gels were
stained with Coomassie blue to look for a protein band of appropriate size. The sample
with the highest amount of protein after induction was chosen and this clone was used to
make and purify the protein of interest. Desired clones were grown in LB broth and
stored at -80°C in cryogenic tubes containing 50% glycerol (1:1 50% glycerol: cell
culture ratio) to make the glycerol stock.
Coomassie blue staining
Gel containing 10% acrylamide was fixed with solution contain 50% ethanol and
7% acetic acid. Then, the gel was immersed in 0.075% stain solution in 10% acetic acid
and 50% ethanol for 10 min and then washed 3X with ddH2O. To destain, the gel was
placed in 100 ml of 5% ethanol and 7.5% acetic acid with gentle agitation and changed to
fresh destain solution every half hour until the gel was clean enough to see protein bands
clearly. The gel was transferred into 0.5% acetic acid and subsequently soaked in 4%
glycerol for 2 hr. The gel was dried at 70°C for 50 min in a gel dryer vacuum system
(BioRad, model 583) and scanned for image.
Purification of proteins from Rosetta bacteria
On the evening of the first day of purification, Rosetta E. coli containing the
appropriate pHH2 plasmid were taken from a glycerol stock and streaked on a LB
(amp+/chlo+) agar plate and grown at 37°C overnight. The plate was removed the next
morning and kept at room temperature until evening. A 40 ml LB (amp+/chlo+) broth
was inoculated with a single colony from the plate and incubated at 37°C and 200 rpm
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overnight in a shaker. The overnight culture was subcultured into 1 L of pre-warmed LB
broth and incubated at 37°C for about 4 hours (until OD600 1.5-1.9). 1 ml of uninduced
sample was taken for gel analysis before adding 1 ml of 100 mM isopropyl β-D-1thiogalactopyranoside (IPTG) and continued shaking for about 4 hours. 1 ml of induced
sample was also taken for gel analysis. The 1 L culture was then centrifuged in 500 ml
bottles at 8,500 rpm, 4°C for 10 min in a Sorvall centrifuge. The pellet was stored at 80°C with 400 µL of 100 mM PMSF.
Pellets from the 1 L culture were resuspended in 10 ml 2X L&C buffer (Trisbased elution buffer; 400 µL 1 M Tris, pH 8.0, 0.35 g NaCl, 2 ml glycerol in 10 ml
solution), 10 ml 2X protease inhibitors cocktail (Sigma-Aldrich, St Louis, MO Cat #
S8830), 40 µL 0.5 M EDTA and 20 µL 1 M DTT. The resuspended cells were sonicated
on ice for 6 min with 30 sec pulses and centrifuged at 9,500 rpm at 4°C for 20 min. The
supernatant was filtered through 1.2 micron filters then through 0.2 micron (Whatman,
GE Healthcare REF 10 462 261) to remove any debris. The clarified lysate was pumped
through a Fractogel GST-bind cartridge (EMD) using a BioRad pump at 4°C according to
the manufacturer’s instructions. The Fractogel cartridge bound the GST-tagged proteins
while other synthesized proteins pass through the column. Briefly, after pumping the
lysate through the cartridge, the column was washed with 2 ml 1X L&C buffer, followed
by 5 ml ATP wash buffer (2X L&C buffer, 10 mM ATP, 50 mM MgCl2, 1.3 ml ddH2O)
and finally, 12 ml 1X L&C buffer containing 1 mM DTT and 1 mM EDTA. To excise
protein without any tag, a GST-tagged PreScission protease mix (1 ml L&C buffer
containing DTT and EDTA and 50-100 µL of protease) was pumped in the column and
allowed to circulate through the system for 4-6 hours. Typically, the protease was
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originally at 1.5-6 mg/ml and desalted. The material in the recirculated tube was collected
as elution 1 (E1). L&C buffer containing DTT and EDTA was pumped through the
column to collect at least 3 more fractions of about 1 ml each and labeled E2, E3 and E4
respectively. The fractions contained tag-free proteins which were quantified and the
quality verified using SDS-PAGE. 4 ml of reduced glutathione buffer (0.01 g/ml of 1X
L&C buffer) without DTT or EDTA was pumped into the column to remove the GST
tags and protease and the column was subsequently washed with 10 ml L&C buffer
without DTT or EDTA to regenerate the column for future use. The column was stored at
4°C for other purifications while the purified protein was stored at -80°C. In any situation
where GST-tagged protein was purified, the bound protein was eluted directly with
reduced glutathione after washing thereby skipping the use of protease. In other
situations, where a GST tagged protein band is noticed with the pure protein, the GST
protein was removed by incubating with GST slurry beads (Goldbio, MO) for 4 hrs at
4°C. The protein-slurry mixture was separated by centrifugation at 4°C, then the pure
protein is taken to be dialyzed. Results showed a high yield of pure protein of both PDZ1
and PDZ3 domain (Figure 11). ADAM17 cytoplasmic domain was cloned and purified
using the same approach. First, ADAM17 coding sequence was confirmed by double
digestion and sequencing (Figure 12). Then, ADAM17 cytoplasmic domain was cloned
in pHH2 plasmid, transfected into Rosetta cells, and the protein was purified as explained
above. A high concentrated purified ADAM17 cytoplasmic domain (MW = 17 KD) was
eluted (Figure 13). Note that the protein band intensity decreases as more protein was
eluted from the column (Figure 13).
Protein dialysis

47

Proteins were purified with a Tris-based buffer that did not allow proper labeling
of the proteins with fluorophores for subsequent experiments. Tris-based buffer was
replaced by dialysis against 3 changes of 2 L dialysis buffer (PBS) at 4°C for minimum
of 16 hours (2 hrs; 2 hrs; overnight) using a Slide-a-lyzer dialysis cassette (Thermo
scientific). Each cassette was removed aseptically from its pouch and immersed in
dialysis buffer for 2 min to hydrate the membrane. 2 ml protein sample was added and
the cassette was floated vertically in the dialysis buffer and stirred gently. A syringe was
used to transfer protein samples into and to remove samples from the cassette after
dialysis as directed by the manufacturer.
Protein labeling
Purified MAGI-1 PDZ domain proteins without GST tag were labeled with
FluoroLinkTM Ab Cy3 labeling kit (GE Healthcare Cat # PA33000) according to the
manufacturer’s recommendations. Protein solution (1 mg/ml) was added to the vial of
coupling buffer, mixed gently, then transferred to the vial of reactive dye and incubated at
room temperature with mixing every 10 minutes. While the labeling reaction was
incubating, 13 ml of fresh elution buffer was added to the column for priming. The
antibody-labeling mixture was carefully added to the top of the column and allowed to
enter the resin. 2 ml of elution buffer was added to the column to separate the mixture
into a faster moving pink (Cy3) band of labeled protein from the unconjugated dye. An
additional 2.5 ml of elution buffer was then added to the column that will help to elute the
pink band. The labeled protein was collected in a clean tube.
Quantification and calculation of D/P ratio
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Cy3 bisfunctional dye characteristics Cy3
Formula Weight 949.11
Absorbance max 550nm
Extinction max 150000M-1cm-1
Emission max 570nm
Quantum Yield >0.15*
* = for labeled proteins, D/P = 2
An aliquot of the labeled protein was diluted such that the maximum absorbance
was 0.5 to 1.5 AU. The absorbance of each labeled protein was measured at 280 nm, 552
nm (Cy3) after which protein concentration was determined with Bio-Rad reagent.
Estimation of Cy3 final Dye/Protein (D/P) Ratios
[Cy3 dye] = (A @ 552nm) / 150000 ( [ ] )= concentration)
[Protein] = [A @ 280nm – (0.08 * A @ 552nm)]/ molecular weight of protein
D/P final = [dye]/[protein]
Graphing and data analysis
All graphs and data analysis were made using Prism software version 6
(GraphPad, CA). Each experiment was done in triplicate and data were plotted as Mean±
SEM. The binding affinity (Kd) was determined using the function of non-linear
regression- one site specific binding.
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Figure 11. MAGI-1 PDZ domains protein purification.
PDZ1 and PDZ3 were purified using GST-tagged column purification. A band at 25
KD and 23 KD were obtained which correspond to PDZ1 and PDZ3 domain,
respectively. Note that further purification was done to remove any GST tagged PDZ
domain.
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Figure 12. Confirmation of ADAM17 coding sequence using restriction enzyme
double digestion of the vector.
A band of 3 kbp, corresponding to the expected length of the gene for ADAM17
(arrow), was detected upon double digestion with NotI and KpnI.
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Figure 13. Purification of ADAM17 cytoplasmic domain by GST column
purification.
The cytoplasmic domain of ADAM17 has MW of 17 KD. Elution 1 and 2 (E1, E2) had
highly concentrated purified protein. Note that the band intensity decreased as more
protein is eluted from the GST column. The upper band was mostly likely uncleaved
GST-ADAM17 or precision protease. E1 and E2 were subsequently incubated with
GST-beads to remove remnant GST proteins (data not shown). FT, flow through; L&C,
wash step; ATP, wash step; E1-5, elusions.
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Immunoprecipitation and Western blot
Cell cultures were placed on ice for 5 min, washed with ice-cold PBS, and lysed
in buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, protease inhibitors (20
µg/ml, leupeptin, aprotinin, 10 µg/ml pepstatin, and 17.4 µg/ml phenylmethylsulfonyl
fluoride)) by rocking at 4°C for 10 min. Cells were scraped into a tube, sonicated five
times with 5 pulses using Sonic Dismembrator (Fisher Scientific, model 100) and
centrifuged at 14,000g for 10 min at 4°C. The supernatant was transferred to fresh tubes
and subjected to protein estimation by Bio-Rad protein assay according to manufacturer’s
instructions. Aliquots of each lysate were saved for Western blot analysis of total protein
in immunoprecipitation (IP) or co-immunoprecipitation (co-IP) experiments. For IP or
co-IP, an appropriate amount of primary antibody was added to pre-cleared equal protein
concentration of sample lysate in Eppendorf tubes and rotated at 4°C for 4 hours. Protein
G Sepharose beads slurry (GE Healthcare) was prepared by washing 3 times with 2X
volume of lysis buffer and once with lysis buffer minus Triton X-100, followed by
resuspension in fresh lysis buffer (50% beads + 50% buffer). 50 µL washed beads was
added to each sample tube with additional rotation at 4°C for overnight. Samples were
washed 3 times with lysis buffer and once with lysis buffer minus Triton X-100 by
centrifugation at 17000 rcf, 4°C for 1 min to pellet beads. Each IP sample was
resuspended in 70-100 µL 2X denaturing buffer with dye (for WB) and incubated in a
heat block at 65°C with shaking at 300 rpm for 10 min. Samples were then immediately
vortexed vigorously before spinning at 17000 rcf, 30-60 sec. Only supernatant was
subjected to SDS polyacrylamide gel electrophoresis (10% unless otherwise indicated).
Proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford,

53

MA), blocked with 5% BSA in TBS-T, washed, probed with appropriate antibody diluted
in 2% BSA in tris-buffered saline tween-20 (TBS-T) with sodium azide, followed by
HRP-conjugated secondary antibodies (Jackson Immuno Research, West Grove, PA)
diluted in TBS-T (1: 10,000). Protein bands were detected by adding ECL reagents
(Pierce, Rockford, IL) and imaged on a ChemiDocTM MP imaging system (Biorad, CA).
Cell surface biotinylation
Cell surface proteins were biotinylated with 3 ml per 100 mm plate of 1 mg/ml
sulfo-NHS-biotin (Cat # 21331 Thermo Scientific, Rockford, IL) for 1 hour at 4°C after
first cooling cells on ice for 10 min and washing with ice cold PBS +/+. After washing
the cells again with PBS +/+, any unreacted biotin was quenched with 100 mM glycine
for 20 min at 4°C. Washed cells were then incubated with lysis buffer for another 20 min
at 4°C. Cell lysate was immunoprecipitated with NeutrAvidin ultra link resin (Cat #
53150 Thermo Scientific) and Western blotting with antibody of interest.
Adenovirus infection
Adenovirus serotype 5 containing the β-galactosidase gene (AdV-β-Gal), or AdVCAREx7, or AdV-CAREx8 (University of Iowa Vector Core, Iowa City, IA) was diluted
with Opti-MEM culture media (Gibco, Invitrogen) without serum to the multiplicity of
infection (MOI) of 100. Growth media was aspirated from cells that had been seeded for
48 hours and the cells were rinsed with phosphate buffered saline containing Ca+2 and
Mg+2 ions (PBS+/+). 250 uL of diluted adenovirus was added to each well in a 24 well
plate (3 ml in 10 cm2 dish) at a MOI of approximately 100 plaque forming units/cell
(PFU/cell), unless otherwise indicated, and incubated for 1 hr at 37°C and 5% CO2 with
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gentle swirling every 15 min. The inoculum was then removed, cells were rinsed with
Opti-MEM, and fresh complete media was added. The cells were then incubated at 37°C,
5% CO2 until further analysis.
Quantitative Polymerase Chain Reaction (QPCR)
The PCR amplification was programmed for 40 cycles at 95ºC for 10 min
(denaturation), 58ºC for 1 min (annealing), and 60ºC for 1 min. (extension). qPCR was
performed using SYBR Green with low ROX (Quanta, Gaithersburg, MD; 10µl master
mix qPCR reaction contained 2μl DNA, 2X reaction buffer with dNTPs, Accusat Taq
DNA polymerase, MgCl2 ROX reference dye and SYBR green dye that binds specifically
to dsDNA) in Stratagene's Real Time PCR System (Agilent Technologies) using
Mx4000p software v5 for data analysis.
Beta-galactosidase assay
The Galacto-Light Plus System (Applied Biosystems, USA) was used to analyze
adenovirus-mediated beta-galactosidase activity according to manufacturer directions.
Briefly, cells were lysed 24 hours after adenovirus infection. 100 µL of lysis buffer were
added to each well in a 24-well plate for 10 min at room temperature. Cells were scraped
and 2 µL of lysate was added into a 96-well plate followed by 120 µL of a 1X TropixGalacton substrate (Applied Biosystems) and 60 min incubation at room temperature. 150
µL of Tropix accelerator II was then added just before measuring β-galactosidase
luminescence in Luminometer. Protein concentration was determined by Bradford protein
estimation according to the manufacturer protocol. The optical density was measured at
spectrophometer wavelength 595 nm as compared to a set of standard. Each experiment
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was performed in 3-6 replicates and lysis buffer was used as control. Data was analyzed
using Prism software (GraphPad, CA).
Nuclear Fractionation
Nuclear fractionation was done as previously described (153), with some
modification. Inducible MDCK- CAREx8 (1*107 cells) were induced with 50 ng/ml of
Dox for overnight. The next day, cells were treated with either TAT-NET1, TAT-E6 or
TAT-scramble peptides for 4-5 hrs. By the end of the treatment period, cells were
transferred into 4 ºC and kept for 10 min, washed with PBS without calcium and
magnesium 3 times. Cells were lifted using Nelson lifting solution (NaHCO3 4.2 mM,
glucose 5.6 mM, NaCl 137 mM, KCl 5.4 mM, EDTA 0.5 mM. PH 7.2-7.4). After that,
cells were pelleted by centrifugation at 880 rpm for 6 min. The pellet was re-suspended in
50 µl of freshly prepared buffer A (10 mM Hepes, PH 7.9, 10 mM Kcl, 1.5 mM MgCl2,
0.1 mM EDTA, 0.5mM DTT, 0.5% (v/v) NP-40, 1X protease inhibitor cocktail (Pierce
Thermo scientific, MA)). Samples were centrifuged at 800 x g for 10 min at 4ºC and the
supernatant was collected as the cytoplasmic extracts. Then, the pellets were resuspended in 50 µl of buffer B (20 mM Hepes, PH 7.9, 400 mM NaCl, 1.5 mM MgCl2,
0.1 mM EDTA, 5% glycerol, 0.5 mM DTT, 1X protease inhibitor cocktail (Pierce
Thermo scientific, MA)) in order to extract the nuclear proteins. After incubation for 30
min on ice, samples were centrifuged at 10,000 x g for 30 min at 4 ºC. The supernatant
was collected as the nuclear extract. A Bradford assay was done to confirm equal protein
loading, and samples used immediately for Western blot.
Preparation and collection of conditioned media
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For CAREx8 or CAREx7 extracellular domain shedding, 2 x 106 – 4 x 106 inducible
MDCK (60) cells were seeded per well in 6-well plate. The following day, cells were
washed with PBS containing calcium and magnesium and induced overnight with 50
µg/ml Dox. The day after, cells were washed with PBS and treated with Tat-peptides
(final concentration 100 µM or as indicated in the text) in serum deprived media for 4-5
hrs. The conditioned media were collected in pre-chilled tubes, cleared of cell debris, and
rotated at 4ºC for 2 hrs with mouse anti-Flag antibody (Fisher scientific, MA). Protein G
Sepharose bead slurry (GE Healthcare) was prepared by washing 3 times with opti-MEM
media, and 40 µL of washed beads was added to each sample tube with additional
rotation at 4°C for overnight. The next day, beads were precipitated by centrifugation at
4°C then washed 3 times with Opti-MEM. Finally, precipitate was eluted with
Laemmli/2-mercaptoethanol buffer and subjected to SDS-polyacrylamide gel
electrophoresis (10% unless otherwise indicated). Proteins were transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA), blocked with 5%
BSA in TBS-T, probed with rabbit anti-Flag (Millipore, MA) to detect the shed CAR
ECD. The membrane was also stained with Ponceau S stain to confirm equal loading.
Preventing AdV infection by the shed CAR ECD
Conditioned media from vehicle, TAT-scramble, TAT-NET1, or TAT-E6 treated
MDCK epithelia was collected and incubated with AdV-GFP (MOI 100) for 30 min at 37
ºC with slight shaking. Hela cells were infected with the mixture for 1 hr after which
media were replaced with complete media. To remove the CAREx8 ECD, conditioned
media were pre-cleared using antibody specific for the ECD of CAR (mouse anti-Flag).
24 hrs post infection, cells were washed with PBS 3 times and images were taken at 20 x
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magnification power. Image analysis was done using Metamorph software as previously
described.
Ponceau S Stain
Ponceau S stain (Sigma-Aldrich, MO) was prepared in 0.1% (w/v) in 5% (v/v)
acetic acid. A PVDF membrane was incubated with Ponceau S stain for 15 min at room
temp. To destain, the membrane was placed in 10 ml of 10% (v/v) acetic acid solution for
10 min and scanned for imaging using ChemiDocTM MP imaging system (Bio-Rad, CA).
RNA extraction
RNA extraction was done using GeneJET RNA purification kit (Thermo
scientific, MA), according to the manufacturer protocol. Epithelial cells (5*106) or lung
tissue (30 mg) were lysed using lysis buffer containing β-mercaptoethanol on ice. The
lung tissues were homogenized using mortar and pestle in 300 µL until suspension is
uniform. Once homogenized, proteinase K (600 µl) was added to the mixture and vortex
then incubated for 10 min at room temperature to insure homogenous solution. Mixture
was then centrifuged at 4ºC for 10 min at 13,500 x g, and it was transferred to RNA free
tube. Repeated administration of the lysate (up to 700 µl) was added into RNA
purification column. Each time, the column was centrifuged at 13,500 x g for 1 min and
the flow through was discarded. The column was washed twice with wash buffer 1, and
wash buffer 2. Finally, the RNA was eluted with ribonuclease free water added to the
center of column. Gloves were change between each steps and aseptic technique were
taken in consideration to minimize RNA degradation. The RNA was directly used to
make cDNA for further experiment.
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Reverse PCR and cDNA synthesis
Freshly isolated RNA was subjected to cDNA using qSriptTM cDNA SuperMix,
according to the manufacturer protocol. 1 µg of total RNA was incubated with 1x dilution
of cDNA supermix in a total volume 20 µl using 0.2 ml micro tubes. After sealing each
reaction properly, the tubes were vortexed and centrifuged briefly to collect the mixture
at the bottom of the reaction tube. The mixture was loaded into 96 wells plate and sealed
with plastic cover. All steps were performed on ice to minimize ice. The PCR setting was
programmed for 40 cycles 5 min at 25ºC, 30 min at 42ºC, and 5 min at 85 º C, the plate
was hold at 4ºC. After cDNA was completed, 1/10 of the first strand reactions were used
for PCR amplification.
Immunocytochemistry
Cells were kept on ice for 5 min, washed 3 times with ice cold PBS supplemented
with Mg2+ and Ca2+ (PBS +/+). The cells were then fixed with methanol containing 1%
paraformaldehyde for 20 min at -20°C. Cells were rinsed with ice cold PBS, allowed to
come to room temperature, and blocked with 2% bovine serum albumin (BSA) in
SuperBlock (Pierce, Rockford, IL) for 45 min. Appropriate primary antibodies were
added to cells for 2.5 hrs at 37°C or overnight at 4°C. Cells were rinsed 5 times with PBS
with the last rinse greater than 10 min. Cells were blocked with 2% BSA in Superblock
for 5 min and then incubated with appropriate Alexa-labeled secondary antibodies
(Invitrogen) for 2 hrs at 37°C. The cells were rinsed 5 times with PBS and mounted onto
glass slides using Vectashield mounting media with DAPI (Vector Laboratories Inc.,
Burlingame, CA). Staining was evaluated by laser scanning confocal microscopy
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(Olympus FV1000) with a 60X oil immersion lens; images are shown as either single XY or X-Z sections.
Plasmid transfection
Cells were transfected with plasmids 24 hours after seeding, when cultures
reached over 60% confluence with Xfect (COS-7) transfection reagent (Clontech).
Transfected cells were used for immunoprecipitation, Western blot. GFP plasmid was
transfected into separate wells, under the same conditions with the cloned domains to
monitor transfection efficiency. All experiments included both positive and negative
controls, as described in the text, and were repeated a minimum of three times unless
otherwise indicated. COS7 cells were transfected with the cloned domain plasmids to
confirm protein expression by immunocytochemistry and Western blotting. MDCK cells
were transfected using GenJet transfection reagent (SignaGen Laboratories) at the time of
seeding (reverse transfection) to give 56-60% confluency after 24 hrs.
SiRNA Transfection
SiRNA targeting different parts of MAGI-1 gene (StealthTM) were purchased from
Invitrogen Custom Laboratory Services (Carlsbad, CA) as dry pellets. siRNA that targets
different parts of ADAM17 gene were purchased from Dharmacon (Lafayette, CO).
Each siRNA duplex was re-suspended in RNase-free water to make a 20 mM solution.
siRNA duplex was transfected at the time of cell seeding at concentrations (20-30 µM)
into MDCK cells (reverse transfection) using Dharmacon transfection reagent I. Cells
were then seeded with the appropriate number of cells that would give 50-60%
confluence 24 hours after plating. Cells were incubated at 37°C, 5% CO2 for 48-72 hrs.
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Non-targeting siRNA sequence (ON-TARGET plus) were used as a control for siRNA
transfection. Validation of the level of MAGI or ADAM17 knockdown was done by
evaluation of WB.
ADAM17 activity assay
ADAM17 activity was performed as described before with slight modification
(154). Briefly, 20 µg of protein lysate in assay buffer (50 mM Tris, 5 mM ZnCl2, 150
mM NaCl, and 10 µg/ml TIMP1, pH 9) was pre-incubated with DMSO or ADAM17
inhibitor (TIMP3) for 30 min at 37ºC. Then, internally quenched fluorogenic substrate
Mca-PLAQAV-Dpa-RSSSR-NH2 (Enzo Life Sciences) was added to the mixture (final
concentration 50 µM) and incubated for 10 min. Fluorescence was measured at an
excitation of 328 nm and emission of 393 nm using a Synergy H1 microplate reader
(Biotek, VT). The enzyme activity calculation was done according to the manufacturer
recommendation. Values were normalized to the protein concentration of each sample.
Cell polarization and TER measurement
For polarization studies, 2 x 104 – 2 x 106 cells per well were seeded on 10 mm
diameter polyester tissue-culture treated Millicell filters with a pore size of 0.4μm
(Millipore, Bedford, MA). Media on the apical surface of cells was removed the next day
and the apical surface was maintained dry in order to establish an air-liquid interface.
Polarized cells actively transport fluid from the apical to the basolateral surface and thus
maintain a defined apical surface fluid composition.
Transepithelial electrical resistance was measured with a chopstick ohmmeter
(World Precision Instruments, Sarasota, FL) every other day (Figure 14). When this
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measurement was taken, media was aspirated from the wells and replaced with 600 µL
fresh media at the basolateral surface. 400 µL of PBS supplemented with Ca2+ and Mg2+
was applied to the apical surface. The background electrical resistance was determined by
adding media to the basolateral chamber and PBS to the apical chamber of a blank
Millicell filter. The TER measurements were recorded in mohm (mΩ).
FITC Dextran assay
Assessment of epithelial integrity after peptide treatment was done using FITCdextran assay as described before (155). Briefly, primary human airway epithelial cells
were seeded on millicells and allowed to polarize as described in the TER measurement
section. FITC-Dextran 4 kD or FITC-Dextran 70 kD (Sigma-Aldrich, MO) were prepared
as stock solution (10 mg/ml) in ultrapure water and sterilized by filtration through a 0.22
µM pore size filter. Cells were washed with PBS containing calcium and magnesium,
from the apical and basolateral side. 150 µl of pre-warmed FITC-Dextran in PBS (final
concentration= 0.5 mg/ml) were added to the apical surface and 450 µl of PBS were
added to the basolateral (Figure 14). After incubation for 120 min at 37 ºC, basolateral
medium was collected, cells were washed with PBS and TER measurement were taken
again. Controls for this experiment included the calcium chelating agent (EDTA) as well
as the detergent Triton X-100 treatment for 10 min prior to the FITC-Dextran addition.
EDTA chelates the calcium required for cadherin based adhesion and transiently breaks
the junctions. Triton X-100 destroys the epithelial integrity by membrane
permeabilization and it is used to assess to what extent the tracer molecules bind to
remaining cellular components and debris (155). TER measurement were taken before
and after treatments to confirm disruption of the epithelial tight junctions.
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By the end of the 2 hrs, 100 µl aliquots were taken from the basolateral chamber
and transferred to a 96-well plate for determination of relative fluorescence intensity
(RFU) in a pre-calibrated Synergy H1 microplate reader (Biotech, VT) using software
Gen5 2.04. A standard curve of each FITC-Dextran was established using range of
concentration 0-20 µg/ml. The RFU values of the standard curve samples were taken in
triplicates with an excitation wavelength 490 ± 9 nm and an emission wavelength of 520
± 9 nm. The standard curves were used to determine the unknown concentration of the
FITC-Dextran diffused to the basolateral side. Each peptides treatment condition was
done in triplicate.
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Figure 14. Schematic diagram of methods used to assess epithelial cells integrity.
(A) Model of TER measurement as an indicator of epithelial polarization. Transepithelial
electrical resistance (TER) was determined by adding media to the apical and basolateral
chambers. Electrical resistance was taken in mΩ using voltmeter with chopstick electrodes.
(B) Schematic model of FITC-Dextran permeability assay across epithelial cells. FITClabelled dextran was added to the apical surface. Dextran diffusion was assessed by collecting
the basolateral media and measuring at the emission fluorescence of the FITC-dextran.
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FITC-Dextran permeability assay is a good measure of epithelial integrity
In order to validate my approach in using FITC-Dextran as a measure of epithelial
integrity, I optimized the conditions of FITC-Dextran assay in epithelia cells. First,
epithelial cells were polarized on millicells until the TER reaches 1500-3000 Ohm. Then,
the epithelia were treated with PBS, EDTA or Triton X-100 for 10 min at 37°C. In no
treatment or PBS treatment condition, no significant change in the TER detected from
baseline (Figure 15). In contrast, treatment with EDTA or Triton X-100 significantly
dropped the TER (Figure 15), indicating that the measured TER was due to the tight
junctions between epithelial cells. FITC-labelled Dextran permeability is another
indicator of the epithelial integrity. To study the correlation between FITC-Dextran and
the emission fluorescence, serial dilutions of standard concentration of the FITC-Dextran
4 kD and FITC-Dextran 70 kD were prepared. The fluorescence intensity was measured
and standard curve was created for each Dextran. The standard curve of both FITCDextrans gave straight line with R2=0.99 which indicates a linear correlation between the
fluorescence intensity and the amount of FITC-Dextran in the solution (Figure 15).
I used this technology to assess the paracellular Dextran diffusion between
epithelial cells. The procedure was done as explained above. FITC-Dextran 4 kD was
used to assess paracellular flux of small molecules whereas Dextran 70 kD was used to
assess the paracellular movement of large molecules. Under normal conditions (no
treatment), there is traces of Dextran 4 kD that diffused across the epithelia but much less
Dextran 70 kD, indicating intact tight junctions of the epithelia. PBS treatment slightly
increased the diffusion of Dextran 4 kD but not Dextran 70 kD (Figure 15). Interestingly,
treatment with EDTA (Ca+2 ion chelator) significantly increased the amount of Dextran 4
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kD only, indicating partial disruption of the adherens junctions (Figure 15). Treatment
with Triton X-100 significantly increased the diffusion of both Dextrans indicating
complete perturbation of the cell junctions (cell lysis). This result further validates the
applicability of the FITC Dextran diffusion assay as an indicator for epithelial integrity
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Figure 15. Optimization of FITC-Dextran permeability assay.
MDCK Epithelia were polarized and TER measurements were taken after 10 min of
(A) no treatment (B) treatment with PBS (C) Treatment with 8 mM EDTA or (D) 1 %
Triton, *p < 0.05 vs baseline. (E) FITC-dextran emission fluorescence correlated with
the amount of FITC-dextran in solution. Serial dilution of FITC-dextran 4 kD and
FITC-dextran 70 kD were prepared and excitation-emission fluorescence were
measured at wavelength 490 ± 9 nm and 520 ± 9, respectively. (F) FITC-dextran
permeability across polarized epithelial cells seeded on millicells. Cells were not
treated, treated with PBS, EDTA, or Triton for 10 min at 37°C. *p < 0.05 compared to
baseline or no treatment.
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Vesicle trafficking by Rabs
The Rab Family antibody sampler kit (cell signaling, MA) was used to investigate
the CAREx8 trafficking pathway. Polarized inducible MDCK cells were induced overnight
with 500 ng/ml of dox. The next day, cells were incubated with protein synthesis
inhibitor cycloheximide (100 mg/mL) for 4 h at 15-20°C to accumulate newly
synthesized CAREx8 in the trans-Golgi network (TGN). By the end of the 4 hrs, TGN
cargo was released by incubation at 37°C for 5-15 min (156). By the end of the release
time, cells were washed with PBS and fixed immediately with 1% PFA in methanol.
CAREx8 was stained with mouse anti-Flag and Rabs were probed with rabbit anti-Rab Ab.
In some optimization conditions, FITC-labelled Wheat Germ Agglutinin (WGA) was
used as a cell marker for the trans-Golgi compartment. Images were taken using FV1000
confocal microscopy (Olympus, NJ).
Animal handling and peptide administration
Animals (Tom/ CC10 and Tom/Spc background, JAX stock # 007576) were
housed individually (male) or in groups (females) at 22°C under a 12-hour light/12-hour
dark cycle with ad libitum access to water and standard mouse chow (3.0 kcal/g, 40.6%
carbohydrate, 5.5% fat, and 22% protein; Harlan Teklad, Madison, WI). All experimental
protocols were approved by the WSU Animal Care and Use Committee. Animal were 812 weeks old were originally purchased from Jackson laboratory and bred at the
University of Iowa animal facility. Mice were anesthetized moderately using isoflurane in
a closed chamber. Once the animal was knocked out, mice were removed quickly from
the chamber and were held in 60° declined supine position by securing the fore and hind
paws with the left hand. A sterile P200 pipette was used to deliver a volume of 50 µl in the
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left nostril of the mouse during inhalation. Mice were given a dose of 500 µM of peptides
dissolved in a volume of 50 µl of vehicle (PBS) via intranasal administration. Four hrs
later, mice were infected intranasal (through the right nostril) with AdV-Cre (University
of Iowa, IA). Virus dose 1.0*108 PFU/50µl. After each intranasal administration, mice
were held straight for few minutes to assure that all solution was inhaled. Then, they were
returned to their cages for recovery to allow Cre-recombinase expression. Approximately
2 days later mice were euthanized by CO2 inhalation. A 10 mm incision was made over
the trachea of mice to visualize the insertion of tracheal intubation (size 60 - polyethylene
(PE) tubing; Becton Dickenson and Co., MD, USA). Tube was moved down to the point
of tracheal bifurcation and slid gently toward the left lung. At the point of left lung
bifurcation, the distal trachea was tied but not secured along with the tracheal tube using
(6-0 nylon; Ethicon). The right tracheal biforation was tied and secured. A solution
contains 50% PBS and 50% tissue freezing media (Thermoscientifc, MA) was infused
through the intratracheal tube using 20 ml syringe (Fix inflation). Once inflated, the knot
was secured. Another knot was made in the proximal trachea and below the intubation
site. The trachea and the left lung were then dissected, wrapped in foil and frozen in dry
ice for 2 days. The right trachea was cut distal to the knot secured site. One lobe was
submerged in RNA later (Thermofisher, MA) for RNA isolation. The other two lobes
were dissected and frozen in liquid nitrogen for 2 hrs before they were transferred to dry
ice. The left lung and trachea were fixed frozen in Tissue Freezing Medium (TFM) after
removal of intubation tube. Lung lobes were cut sectioned in 25 micron sections using
cryostat HM550 (Thermo scientific, MA). Sections were then vapor fixed in a chamber
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containing 4% paraformaldehyde. After that they were visualized for red and green
fluorescence expression using FV1000 (Olympus, NJ).
Statistics
All statistical analysis was done using Prism software (GraphPad, CA).
Depending on the experimental condition, a T-test, one way or two-way Analysis of
Variance (ANOVA) was performed. Tukey post hoc test was used to compare the all
pairs of means. P value < 0.05 was considered as statistically significant.
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CHAPTER 3: Investigation of the Effect and Molecular Mechanism of TAT-PDZ1
Peptides on CAREx8 and Adenovirus Infection
Rationale
Adenovirus (AdV) and coxsackievirus group B (CVB) infections can be severe and life
threatening and no specific or effective therapeutics currently exist. Understanding the
mechanisms leading to decreased susceptibility of the airway epithelium to viral infection
will improve both therapeutic options and patient outcomes in the future. The discovery
of the regulatory role of MAGI-1 on CAREx8 opened the door toward a clear and easy
target for controlling AdV infection. CAREx8 contains a PDZ-binding motif that interacts
with two MAGI-1 PDZ domains, PDZ1 and PDZ3, which regulate CAREx8 levels in
opposing ways (Figure 8) (63). While an interaction with PDZ3 causes CAREx8
degradation and reduces AdV infection, interaction with the PDZ1 domain is able to
rescue CAREx8 from degradation and increase AdV infection (63). This chapter is focused
on identifying the mechanism behind MAGI-1 PDZ3-mediated CAREx8 downregulation
using peptide-based molecules that block MAGI-1 PDZ1. The net result is CAREx8
degradation and the decreased apical AdV infection in polarized cells. Such therapeutics
will be used for pre-clinical evaluation to suppress AdV infection in vivo
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Results
Epithelial cells line most organs and form a strong barrier that protects organs
from incoming microorganisms and environmental factors. My approach was to
transduce epithelial cells with a peptide-based sequence that would alter CAREx8 level
and AdV entry. The first challenge was to enhance peptide transduction in epithelial
cells. Rapid transduction of proteins into cells can be facilitated by cell-permeable
peptides (CPP; also called cell penetrating peptides and protein transduction domains)
(115-117). The 11 aa cell permeable HIV-TAT sequence, which is able to facilitates
peptide internalization, was conjugated to the C-terminal 9 aa sequence of the full length
CAREx8, to make TAT-CAREx8-9c. While the last four amino acids of the full length
CAREx8 are the residues responsible for the direct interaction with MAGI-1, the other
residues provide extra PDZ domain specificity. I hypothesized that the designed peptide
sequence would compete with the full length CAREx8 for MAGI-1 binding and release
CAREx8 from MAGI-1 binding and degradation.
TAT- PDZ binding peptides enter epithelial and non epithelial cells
In order to test that the TAT-PDZ binding peptides are capable of entering
polarized epithelial and non-epithelial cells, TAT-CAREx8-9c peptide was synthesized as
described in the materials and methods (Genscript). The entry of the TAT- peptide into
CHO (non-polarized cells that do not express endogenous CAR) and MDCK cells (cells
able to polarize and express endogenous CAR) was confirmed by two approaches. First,
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using matrix assisted laser desorption ionization-mass spectrometry (MALDI-MS), TATCAREx8-9c was detected in lysates from treated cells and spiked cell lysate but not lysates
from untreated cells or cell medium. The synthesized peptide gave a unique and expected
peak at m/z 2536 in the spectrum from both cell lines (Figure 16). The second approach
was done by using fluorescently-labelled TAT-CAREx8-9c. Peptides were synthesized
and conjugated with the red fluorescence protein, Tamra. In both cell lines, the
fluorescently labelled Tamra- TAT-CAREx8-9c entered virtually all of the cells and
localized throughout the cytoplasm with a higher density around the ER/golgi (arrow)
and also, unexpectedly, within the nucleoli (Figure 17). These results validate my
approach of using the TAT cell permeable peptides to facilitate peptide entry into
epithelial and non-epithelial cells.
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Figure 16. TAT-cell permeable peptides enter non-epithelial and epithelial cells.
MALDI-TOF analyses of TAT-CAREx8-9c peptides associate with (A) CHO cells
(non-epithelial) and (B) MDCK epithelia. A peak at m/z 2536 showed in both cell lines
corresponded to the m/z of TAT-CAREx8-9c. CHO or MDCK were incubated with
either TAT-CAREx8-9c or vehicle for 1 hr at 37°C. Cell pellets obtained were used for
MALDI-TOF mass spectrometric analysis as described under Materials and Methods.
TAT-CAREx8-9c enters cells and peaked at m/z 2536.
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Figure 17. TAT-Cell permeable peptides enter non-epithelial and Slide epithelial
cells.
(A) CHO or (B) MDCK cells were treated with either vehicle (PBS) or fluorescently
labelled TAMRA-TAT-CAREx8-9c. Peptide was detectable within 1 h after incubation
inside cells. White arrows indicate ER/Golgi region of cell with intense TAMRA (red)
fluorescence. Confocal 60x oil immersion lens, White line = 10 µm.
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TAT- PDZ binding peptides perturb CAREx8 MAGI-1 interaction
Since the full length CAREx8 can interact with both MAGI-1 PDZ1 and PDZ3, I
tested if the designed TAT-CAREx8-9c would be able to perturb the interaction between
MAGI-1 and CAREx8 in the epithelial cells. I used immunoprecipitation to reveal the
physical uncoupling of CAREx8 and MAGI-1 upon treatment with TAT-CAREx8-9c, using
the advantage of inducible CAREx8 MDCK epithelial cells that express Flag-CAREx8
(60). As expected, MAGI-1 was co-immunoprecipitated with Flag-CAREx8 in the vehicle
treatment condition. In contrast, co-immunoprecipitation of MAGI-1 with Flag-CAREx8
was markedly decreased in MDCK cells pre-treated with TAT-CAREx8-9c. Interestingly,
pre-treatment with TAT-CAREx8-9c that contains mutated PDZ binding motif (TATCAREx8- AA-9c), did not affect co-immunoprecipitation of MAGI-1 with Flag-CAREx8
(Figure 18). These results indicate that the TAT-CAREx8-9c peptide, but not the mutated
peptide, is able to disrupt the cellular interactions between the full length CAREx8 and
MAGI-1 through the PDZ binding motif of CAREx8.
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Figure 18. TAT-cell permeable peptides interrupt MAGI-1-CAREx8 interactions.
Western immunoblots showing immunoprecipitates (IP, left lanes) from inducible
MDCK-CAREx8 epithelia pretreated with TAT-CAREx8-9c or control TAT-CAREx8AA-9c. Stable MDCK-CAREx8 cells were induced with 200 ng/ml Dox for 24 hrs.
After overnight induction, cells were treated with either TAT-CAREx8-9c or TATCAREx8- AA-9c (100µM). CAREx8 was immunoprecipitated using flag antibody.
MAGI-1 was blotted to determine co-IP. Note the marked reduction in MAGI-1
coimmunoprecipitated with Flag-CAREx8 from MDCK pretreated with TAT- CAREx89c. Right lanes show cell lysate with no immunoprecipitation, acting as positive
controls. Note that there was no difference in CAREx8 protein level in the IP blot
possibly due to the increased CAREx8 production induced by doxycycline.
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TAT- PDZ1 peptides binds selectively to MAGI-1 PDZ1
In order to identify small molecules that could decrease apical CAREx8 protein
expression, novel cell-permeable peptides that bind the PDZ1 domain of MAGI-1 were
developed (Table 4). Target sequences were based on published interactions between
cellular NET1 and viral HPV16 E6 with MAGI-1 PDZ1 (112, 144). I tested the
specificity of my peptides to MAGI-1 PDZ domains by a fluorescence binding assay. The
purified PDZ1 and PDZ3 domains were labelled with the Cy3 fluorophore and tested for
interactions with the synthesized TAT-PDZ peptides. In contrast to TAT-scramble
peptide which showed no interactions with either PDZ1 or PDZ3 (Table 4), TATCAREx8-9c bound both domains, with higher affinity to PDZ3 than PDZ1 (Table 4). By
contrast, TAT-NET1 showed an interaction with MAGI-1 PDZ1 (Kd=28 ± 11 nM) but
not PDZ3 (Kd = N.I, No Interaction) (Figure 19). Similarly, TAT-E6 bound MAGI-1
PDZ1 (Kd = 15 ± 4 nM) but not PDZ3 (Kd = N.I, No Interaction) (Figure 20). These
results indicate the selectivity of the designed TAT-PDZ1 selective peptides, TAT-NET1
and TAT-E6, toward the MAGI-1 PDZ1 domain.
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Figure 19. TAT-NET1 binding peptides bind selectively to MAGI-1 PDZ1
domain.
Ligand binding assay between TAT-NET1 peptide and purified MAGI-PDZ-1. MAGI1 PDZ3 domain was used as a control. TAT-NET1 binds to MAGI-1 PDZ1 (A, B) but
not PDZ3 (C, D) (TAT-NET1 Kd=28± 11). Double reciprocal plot (B) showed linear
curve indicating a single binding site between TAT-NET1 and PDZ1 (B) but not PDZ3
domain (D).
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Figure 20. TAT-E6 binding peptides bind selectively to MAGI-1 PDZ1 domain.
Ligand binding assay between TAT-E6 and purified MAGI-PDZ-1. MAGI-1 PDZ3
domain was used as a control. TAT-E6 binds to MAGI-1 PDZ1 (A, B) but not PDZ3
(C, D) (TAT-E6 Kd=15± 4). Double reciprocal plot (B) showed linear curve indicating
a single binding site between the ligand and PDZ1 (B) but not PDZ3 domain (D).
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TAT-PDZ1 selective binding peptides diminish CAREx8 protein levels and suppress
AdV transduction
As TAT-PDZ1 peptides interact selectively with the MAGI-1 PDZ1 domain, I
tested whether the TAT-PDZ1 peptides were able to promote CAREx8 degradation. First,
I tested the cancer epithelial cell line, MDCK. Treatment with TAT-NET1 or TAT-E6
significantly decreased the protein level of CAREx8 (Figure 21). To assess the effect of
TAT-PDZ1 peptides on AdV transduction, MDCK epithelia were treated with vehicle,
TAT-scramble, TAT-NET1, or TAT-E6. Both TAT-PDZ1 peptides significantly
decreased AdV transduction compare to vehicle treatment as measured by qPCR for the
number of AdV DNA genomes (Figure 21). This corresponded to a decrease in Ad-β-gal
gene expression using the β-galactosidase assay, which indicated reduced viral
transduction (Figure 21). I further tested the effect of TAT-PDZ1 peptides on CAREx8 in a
more clinically relevant model, primary human airway epithelia (HAE). Similar to
MDCK, the level of CAREx8 protein was significantly decreased in the TAT-PDZ1
treated conditions (Figure 22). This also corresponded to a suppression of AdV entry into
the HAE (Figure 22). These data suggest that the TAT-PDZ1 peptides could efficiently
reduce or prevent AdV entry in airway epithelia. I took a further advanced step and tested
the efficacy of TAT-PDZ1 peptides in epithelia from an animal model of AdV
pathogenicity. Using epithelial cells from cotton rats (a well-known animal model for
AdV pathogenesis, (157)) both TAT-PDZ1 decreased the level of CAREx8 protein
compared to TAT-scramble and control treated conditions (Figure 23). Similar to HAE,
AdV transduction was significantly suppressed in the TAT-PDZ1 treated conditions
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(Figure 23). Overall, these data indicate that TAT-PDZ1 binding peptides efficiently and
reproducibly suppress AdV transduction by targeting CAREx8 level.
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Figure 21. TAT-PDZ1 binding peptides decrease CAREx8 protein levels and AdV
transduction in MDCK epithelia.
(A) Western Blotting from MDCK epithelia treated with either TAT-scramble or TATPDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in CAREx8 protein level
was seen in the TAT-PDZ1 treated conditions. Actin was used to confirm equal protein
loading. (B) QPCR of the AdV viral genome showed a significant decrease in AdV
entry into MDCK epithelia treated with the TAT-E6 or TAT-NET1 as compared to
control. (C) B-galactosidase activity assay showed a significant suppression of AdV
transduction in TAT-PDZ1 treated MDCK epithelia. * P < 0.05 compare to PBS.
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Figure 22. TAT-PDZ1 binding peptides decreased CAREx8 protein levels and AdV
transduction.
(A) Western Blotting from Human Airway Epithelia (HAE) treated with either TATscramble or TAT-PDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in
CAREx8 protein level was seen in the TAT-PDZ1 treated conditions. Actin was used to
confirm equal protein loading. (B) QPCR of the AdV viral genome showed a
significant decrease in AdV entry into HAE treated with the TAT-E6 or TAT-NET1 as
compared to control. * p < 0.05 compare to control.
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Figure 23. TAT-PDZ1 binding peptides decreased CAREx8 protein levels and AdV
transduction in cotton rat epithelia.
(A) Western Blotting from cotton rat epithelia treated with either TAT-scramble or
TAT-PDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in CAREx8 protein
level was seen in the TAT-PDZ1 treated conditions. Actin was used to confirm equal
protein loading. (B) B-galactosidase assay showed a significant suppression of AdV
transduction in TAT-PDZ1 treated cotton rat epithelia. *p < 0.05 compare to PBS.
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TAT-PDZ1 binding peptides decreased CAREx8 by inducing degradation of the
translated protein
I next investigated the mechanism by which TAT-PDZ1 peptides decrease
CAREx8 protein. First, I tested if TAT-PDZ1 alters CAREx8 mRNA levels by qRT-PCR.
As expected, there was no change in CAREx8 transcript level upon treatment with TATPDZ1 peptides (Figure 24A). I then tested if TAT-PDZ1 peptides alter CAREx8 protein
degradation. Using the global proteasome and RIP inhibitor (MG-132), the effect of
TAT-PDZ1 on CAREx8 peptides was completely reversed in the MG-132 pre-treated
condition (Figure 24B), indicating that TAT-PDZ1 peptides decrease CAREx8 by inducing
degradation of the full length protein.
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Figure 24. TAT-PDZ1 binding peptides decrease CAREx8 by inducing degradation
of the translated protein.
(A) TAT-PDZ1 peptides do not change CAREx8 transcript levels. RT-PCR from TATPDZ1 pre-treated MDCK epithelia. No change in CAREx8 transcript level was seen
among treated conditions. (B) Western Blotting of TAT-PDZ1 treated peptides in the
presence or absence of the proteosomal and RIP inhibitor, MG-132. Pre-treatment with
MG-132 rescued the full length CAREx8 from TAT-PDZ1 induced degradation.
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Downregulation of CAREx8 protein levels by regulated intramembrane proteolysis
(RIP)
To determine whether TAT-PDZ1 peptides exaggerate the normal cellular
pathways that regulate CAREx8 degradation, I followed the fate of CAREx8 by ICC and
confocal microscopy. In MDCK epithelia, most CAREx8 is at the apical surface while
some is distributed in the cytoplasm (Figure 25A, red). Treatment with TAT-PDZ1
peptides dramatically altered the localization of CAREx8 to nuclear inclusions consistent
with RIP (Figure 25B, C, red). To determine the nature of the CAREx8 nuclear inclusions
after TAT-PDZ1 peptide treatment, the cytoplasmic and nuclear fractions were isolated
from induced MDCK-CAREx8 cells after peptide or control treatment and cell lysis for
Western blotting. The advantage of using inducible MDCK-CAREx8 cells is because that
they express CAREx8 tagged with Flag epitope at the N-terminal extracellular domain
upon induction with Dox (60). In that way, I was able to distinguish CAREx7 from
CAREx8, which otherwise would have identical extracellular domains. As expected,
treatment with TAT-PDZ1-binding peptide decreased cytoplasmic CAREx8 as opposed to
control TAT-scramble and PBS (dilutent) treatments (Figure 26). Moreover, the nuclear
fraction showed a 14 kD fragment, which corresponds to the expected size of the CAREx8
C-terminus, only detectable with C-terminal CAREx8 Ab in the TAT-PDZ1 peptide
treated cells (Figure 26). These results indicate that TAT-PDZ1 peptides target CAREx8
degradation and I hypothesized that this was by inducing regulated intramembrane
proteolysis (RIP).
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Figure 25. TAT-PDZ1 binding peptides change the immunolocalization of
endogenous CAREx8.
(A) CAREx8 (red) localizes mainly at the apical membrane of MDCK epithelial cells
(see xz section). (B) Treatment with TAT-NET1 (50µM) or (C) TAT-E6 (50µM)
causes delocalization of CAREx8 to the nuclear compartment but has minor to no effect
on the junctional staining of MAGI-1 (green). Whit bar =10 µm
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Figure 26. TAT-PDZ1 binding peptides translocate the CAREx8 cytoplasmic
domain to the nucleus.
MDCK CAREx8 cells were induced with 50 ng/ml Dox after which they were treated
with 100 µM of TAT-Scr, TAT-NET1, or TAT-E6. Immunoblotting from cellular
fractionation of MDCK epithelia into cytoplasmic and nuclear fractions is shown.
Treatment with TAT-PDZ1 markedly decreases CAREx8 in the cellular fraction. A 14
KD band corresponding to the cytoplasmic domain of CAREx8 was present in the
nuclear fraction in the TAT-PDZ1 treated conditions. Actin (cytoplasmic) and PCRPYY1 (nuclear) were used to confirm equal protein loading in the cytoplasmic and
nuclear fraction, respectively.
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Considering that most transmembrane proteins undergo RIP by secretases, I tested
if γ-secretase inhibitor (compound E) would reverse the effect of TAT-PDZ1 peptides.
Pretreatment with compound E prevented TAT-E6 induced nuclear translocation of the
cytoplasmic domain of CAREx8 (Figure 27). I confirmed this result by immunoblotting
which showed a decrease in the 14 KD fragment formed upon pre-treatment with γsecretase inhibitor compound E (Figure 28). I further confirmed the effect of comp E on
reversing TAT-PDZ1 peptide by cellular fractionation of the cytoplasmic and nuclear
fraction. Pretreatment with comp E resulted in only a partial rescue of the full length
CAREx8 from TAT-PDZ1 peptide but completely reversed nuclear translocation of the
cytoplasmic domain of CAREx8 (Figure 29). Notably, some 14 KD band was detectable in
the cytoplasmic fraction in the comp E pretreated conditions. This indicates that the TATPDZ1 peptides induce RIP of the cytoplasmic domain of CAREx8 by γ-secretase which
causes the CAREx8 cytoplasmic domain to be translocated to the nucleus. This is
consistent with a previous report of ripping the mouse CAR protein (homologous to
human CAREx8 studied here) cytoplasmic domain by γ-secretase (158).
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Figure 27. Selective gamma-secretase inhibitor (compound E) reverses TAT-E6
induced nuclear translocation of the cytoplasmic domain of CAREx8.
(A) CAREx8 cytoplasmic domain is translocated into the nucleus upon TAT-E6 peptide
treatment. (B) Pre-treatment with comp E reversed the effect of TAT-E6 and rescued
the cytoplasmic domain of CAREx8 from nuclear translocation. White bar= 10 µm
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Figure 28. Selective γ-secretase inhibitor (compound E) reversed TAT-NET1
induced nuclear translocation of the cytoplasmic domain of CAREx8.
Western immunoblotting from MDCK epithelia treated with TAT-NET1 in the
presence or absence of the selective gamma-secretase inhibitor (compound E). Pretreatment with comp E decreased cytoplasmic domain formation of CAREx8 (14 KD),
but did not rescue the full length CAREx8 from TAT-NET1 induced degradation.
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Figure 29. Selective gamma-secretase inhibitor (compound E) reverses TATPDZ1 induced nuclear translocation of the cytoplasmic domain of CAREx8.
CAREx8 cytoplasmic domain is translocated into the nucleus upon TAT-E6 and TATNET1 peptide treatment. Pre-treatment with compound E reversed the effect of both
peptides and rescued the cytoplasmic domain of CAREx8 from nuclear translocation.
However, it did not rescue the full length CAREx8 from TAT-PDZ1 induced cleavage.
Note that the 14 KD band detected in the cytoplasmic fraction is expected to be the
transmembrane and the cytoplasmic domain of CAREx8, however, no difference in
M.wt was noticed possibly due to the small molecular weight (2 KD) of CAREx8
transmembrane domain.
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TAT-PDZ1 peptides induce CAREx8 extracellular domain shedding
Because the mechanism of RIP is usually preceded by shedding of the
extracellular domain (ECD), I tested if the widely expressed membrane metalloprotease
ADAM17 would reverse the effect of TAT-PDZ1 peptides and restore the level of
CAREx8. First, I used nuclear fractionation to see if inhibition of ADAM17 would rescue
ripping of CAREx8. Strikingly, treatment with selective ADAM17 inhibitor (TIMP3)
completely rescued the full length CAREx8 from TAT-PDZ1 induced CAREx8 degradation
in the cytoplasmic fraction (Figure 30). As was the case with comp E treatments,
treatment with TIMP3 ablated the nuclear translocation of the cytoplasmic domain of
CAREx8 (Figure 30A). I further confirmed the role of ADAM17 in TAT-PDZ1 induced
CAREx8 degradation using siRNA that selectively targeted the ADAM17 sequence.
Silencing ADAM17 reversed the effect of TAT-E6 on CAREx8 degradation (Figure 30B).
This revealed that ADAM17 and gamma-secretase are the two enzymes by which TATPDZ1 induce CAREx8 degradation.

95

Figure 30. Silencing ADAM17 reverses TAT-PDZ1-induced CAREx8 degradation.
(A) Selective ADAM17 inhibitor (TIMP3) completely reversed the effect of TATPDZ1 peptides in both the cytoplasmic and nuclear fractions and rescued the full length
CAREx8 from degradation. (B) Silencing ADAM17 did not change CAREx8 levels in the
absence of TAT-PDZ1 peptide, but it completely reversed the effect of TAT-PDZ1
peptide compared to control siRNA. N-term Ab: antibody that detects CAREx8 Nterminal domain (Flag). C-term Ab: antibody that detects CAREx8 C-terminal domain
(5678p). Actin and PCRP-YY1 were used to confirm equal protein loading in the
cytoplasmic and nuclear fraction, respectively.
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Since ADAM17 (also known as TACE) is required for the TAT-PDZ1 effect in
decreasing CAREx8, I tested whether TAT-PDZ1 peptides induced CAREx8 ECD shedding
in the extracellular media (hereafter called conditioned media). As expected, TAT-E6
increased Flag- CAREx8 ECD shedding in the conditioned media of inducible MDCK
cells in a dose dependent manner (Figure 31). This corresponded with a decrease in the
full length CAREx8 protein expression in the cell lysate (Figure 31). Similarly, TATNET1 increased CAREx8 ECD shedding in the media, which was corresponded to a
decrease in the full length protein level of CAREx8 in the cell lysate (Figure 32).
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Figure 31. TAT-E6 peptides induce CAREx8 ectodomain shedding.
TAT-E6 increased CAREx8 ECD shedding in the cell media in a dose dependent
manner. This was corresponded to a decrease in the full length CAREx8 in cell lysate.
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were
treated with increasing concentrations of TAT-E6 (0-100 µM). N-term AB: antibody
that detects CAREx8 N-terminal domain (Flag). C-term AB: antibody that detects
CAREx8 C-terminal domain. Ponceau staining was used to confirm equal loading.
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Figure 32. TAT-NET1 peptides induce CAREx8 ectodomain shedding.
TAT-NET1 increased CAREx8 ECD shedding in the cell media in a dose dependent
manner. This was corresponded to a decrease in the full length CAREx8 in cell lysate.
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were
treated with increasing concentrations of TAT-NET1 (0-200 µM). N-term AB:
antibody that detects CAREx8 N-terminal domain (Flag). C-term AB: antibody that
detects CAREx8 C-terminal domain. Ponceau staining was used to confirm equal
loading.
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ADAM17 inhibitor reversed the effect of TAT-PDZ1 peptide and rescued CAREx8
from degradation
To test the hypothesis that ADAM17 is responsible for CAREx8 ECD shedding
induced by TAT-PDZ1 peptides, epithelial cells were pretreated with increasing
concentration of ADAM17 inhibitor (TAPI-1) followed by treatment with TAT-E6.
Treatment with TAPI-1 decreased CAREx8 ECD shedding and rescued the full length
CAREx8 from TAT-PDZ1 mediated degradation (Figure 33). These data suggest that
ADAM17 is the mediator through which TAT-PDZ1 peptides induce CAREx8
degradation.
TAT-PDZ1 peptides increased CAREx8 degradation is time dependent
I then tested the time course of TAT-PDZ1 action in epithelial cells. Treatment
with a single dose (50 µM, 1hr) of TAT-E6 induces CAREx8 degradation which was
terminated after 24 hrs (Figure 34). In the cell media, TAT-E6 increased CAREx8 ECD
shedding which plateaus at 2-24 hrs post-treatment (Figure 34). This indicates that the
effect of TAT-PDZ1 peptides on CAREx8 degradation is fast and lasts for 24 hrs. It also
indicates that the CAREx8 ECD may be quite stable in the media which may imply a long
lasting protection from AdV infection due to the shed CAREx8 ECD in the culture media
(see section CAREx8 shed ECD reduced AdV transduction).
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Figure 33. TAT-PDZ1 peptides induce CAREx8 ectodomain shedding by ADAM17.
ADAM17 inhibitor (TAPI-1) reversed the effect of TAT-PDZ1 on CAREx8 ECD
shedding in a dose dependent manner. MDCK cells were induced with 50 ng/ml Dox
and pre-treated with TAPI-1 (0-100 µM). Cells were then treated with TAT-E6 (100
µM).
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Figure 34. TAT-PDZ1 peptides induce CAREx8 degradation in a time dependent
manner.
MDCK-CAREx8 epithelia were induced with 50 ng/ml of Dox for 24 hrs, after which
Dox was removed. Cells were then treated with 100µM TAT-E6 peptide and cells
lysed at different time points. (A) Western immunoblotting for CAREx8 protein
expression in MDCK epithelia over time after single dose of TAT-E6 peptide
treatment. CAREx8 degradation is time dependent and the effect of TAT-E6 was
reversed by 24 hrs. (B) Western immunoblotting of CAREx8 ECD in the media after
single dose of TAT-E6 peptides treated MDCK for different time point. CAREx8 ECD
shedding is time dependent and plateau at 2-24 hrs.

102

TAT-PDZ1 peptides do not induce CAREx7 shedding
Due to the fact that CAREx7 and CAREx8 share the same transmembrane and extracellular
domains, it is expected that ADAM17 would also be able to shed CAREx7 upon treatment
with TAT-PDZ1 peptides. Moreover, CAREx7 has been shown to interact with MAGI-1PDZ3 domain (150). To be able to differentiate and track the ECD of CAREx7, I used
inducible MDCK epithelia that overexpress Flag-CAREx7 upon treatment with Dox (60).
In the inducible CAREx7 MDCK epithelia, TAT-PDZ1 peptides significantly decreased
the endogenous protein level of CAREx8 but did not change the protein level of FlagCAREx7 (Figure 35). Moreover, there was no change in the CAREx7 ECD shedding in the
condition media (Figure 35). These data validated the selectivity of the TAT-PDZ1
peptides in targeting the CAREx8 isoform but not CAREx7.
TAT PDZ1 peptides do not change ADAM17 activity
I hypothesized that TAT-PDZ1 peptides would activate ADAM17, which would
mediate CAREx8 shedding followed by RIP. Using a fluorogenic ADAM17 enzyme assay
(154), it was shown that there was no significant change in ADAM17 activity upon TATPDZ1 peptide treatment (Figure 36). Ionomycin was used as positive control for
activating ADAM17 as reported before (159, 160). These data rule out the possibility that
TAT-PDZ1 peptides specifically activate ADAM17 to degrade CAREx8.
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Figure 35. TAT-PDZ1 peptides do not affect CAREx7 shedding.
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were
treated with increasing concentrations of TAT-E6 (0-100 µM). No change in CAREx7
cellular level or ECD domain shedding was noticeable. However, CAREx8 protein is
decreased slightly with increasing doses of the peptides. N-term Ab: antibody that
detects CAREx8 N-terminal domain (Flag). C-term Ab: antibody that detects CAREx8 Cterminal domain. Ponceau staining was used to confirm equal loading of media.
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Figure 36. TAT-PDZ1 peptides do not change ADAM17 activity.
Fluorogenic ADAM17 enzyme assay was done as described in the materials and
methods. Ionomycin was used as a positive control, and selective ADAM17 inhibitor,
TIMP3, was used as a negative control. No significant change in the enzyme activity
was observed upon treatment with TAT-PDZ1 peptides, TAT-NET1 or TAT-E6.
*P<0.05 compare to control.
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ADAM17 interacts with MAGI-1 PDZ2 domain
Another possible hypothesis and explanation of the effect of the peptides is that
ADAM17 interacts with MAGI-1 at the same time as CAREx8. I tested if ADAM17 and
CAREx8 are present in a complex and whether treatment with TAT-PDZ1 peptides would
enhance the affinity/interaction between enzyme and substrate. Cells were transfected
with plasmids encoding empty pcDNA3.1 plasmid, ADAM17, and ADAM17 together
with each of the isolated myc-tagged PDZ domains of MAGI-1 (PDZ0-5).
Immunoprecipitation with a myc-tag specific Ab showed that ADAM17 was coimmunoprecipitated mainly with the MAGI-1 PDZ2 domain (Figure 37). I confirmed
these interactions using the direct binding assay between the C-terminus of ADAM17
(TAT-ADAM17-9c) and the purified MAGI-1 PDZ domains. I tested the ability of the
purified ADAM17 to interact with each MAGI-1 PDZ domain. A high affinity interaction
(Kd = 35 ± 7nM) was detected between the ADAM17 C-term domain and MAGI-1
PDZ2 domain (Figure 38). No interactions were detectable between ADAM17 any other
MAGI-1 PDZ domain by binding assay (data not shown). Therefore, MAGI-1 is an
essential scaffold protein that can bring ADAM17 and CAREx8 into the same complex. It
is likely that treatment with TAT-PDZ1 peptide enhances the close proximity between
the enzyme-substrate complexes, i.e ADAM17-PDZ2 with CAREx8 -PDZ3 domain of
MAGI-1.
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Figure 37. ADAM17 interacts with MAGI-1 PDZ2 domain.
(A) Western immunoblotting showing lysate (top two panels) and immunoprecipitate
(bottom two panels) of COS7 cells co-transfected with ADAM17 alone or each myctagged MAGI-1 PDZ domain. Transfected cells were immunoprecipitated using myc
antibody. ADAM17 was mainly co-immunoprecipitated with MAGI-1 PDZ2 domain.
(B) Schematic model of the interaction between MAGI-1 PDZ2 domain and ADAM17.
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Figure 38. ADAM17 has high affinity interactions with MAGI-1 PDZ2 domain.
(A) Direct binding assay between Cy3 PDZ2 and an ADAM17 C-terminal domain
showed a high affinity interaction with Kd= 35±8 nM. (B) Double reciprocal plots
showed a linear line demonstrating a single binding site.
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TAT-ADAM17-9c reversed the effect of TAT-E6 on CAREx8 and AdV infection
To further validate the ternary complex hypothesis between MAGI-1, ADAM17,
and CAREx8, TAT-peptides were designed to target the MAGI-1 PDZ2 domain. Due to of
the high affinity interactions between ADAM17 and MAGI-1 PDZ2 domain, the last 9 aa
sequence of ADAM17 was synthesized and tagged to TAT (TAT-ADAM17-9c). The
effect of TAT-ADAM17-9c on rescuing CAREx8 from TAT-E6 mediated degradation was
tested in MDCK epithelia. Treatment with TAT-ADAM17-9c in the absence of TATPDZ1 peptide did not change the level of CAREx8, However, TAT-ADAM17-9c rescued
the full length CAREx8 from degradation upon exposure to TAT-E6 in a dose dependent
manner (Figure 39). These data further confirmed the hypothesis of ADAM17 binding to
MAGI-1 PDZ2 domain is important for CAREx8 degradation.
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Figure 39. TAT-ADAM17-9c rescues CAREx8 from TAT-PDZ1 induced
degradation.
TAT-ADAM17-9c peptides do not change CAREx8 under control (basal) conditions.
However, it rescues the full length CAREx8 from TAT-E6 induced degradation in a
dose dependent manner. MDCK epithelia were treated with 50µM TAT-ADAM17-9c
for 1hr prior to 4hrs treatment with 50µM TAT-E6.
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MAGI-1 is an important scaffold protein that brings CAREx8 in close proximity to
ADAM17
To verify the role of MAGI-1 in mediating the effect of CAREx8 degradation by
TAT-PDZ1 peptides, I silenced MAGI-1 by specific siRNA and looked for CAREx8
expression in the absence or in the presence of TAT-PDZ1 peptides. As shown in Figure
40, the MAGI-1 protein was successfully silenced in both the PBS and the TAT-E6
treated condition. I had expected a potential increase in CAREx8 proteins upon MAGI-1
silencing, however, CAREx8 protein expression was not affected by MAGI-1 silencing. As
expected, CAREx8 protein expression was significantly decreased in the TAT-E6 treated
conditions and silencing MAGI-1 rescued the full length CAREx8 from TAT-E6 induced
degradation (Figure 40). This shows that MAGI-1 is an important mediator for CAREx8
degradation by TAT-E6 and supports the ternary complex hypothesis between MAGI-1,
CAREx8, and ADAM17.
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Figure 40. Silencing MAGI-1 reverses the effect of TAT-E6 on CAREx8
degradation.
SiRNA designed to specifically target MAGI-1 protein were transfected into MDCK
epithelia for 72 hrs. Epithelia were treated with either PBS or TAT-E6 for 4-5 hrs
before lysing the cells.
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CAREx8 shed ECD reduced AdV infection
It is plausible that the biological significance of the shed CAREx8 ECD is to act as
protective mechanism against AdV entry. Soluble CAREx8 ECD has been successfully
used by many authors to prevent AdV and CVB infection in vitro and in vivo (161, 162).
Conditioned media from Dox-induced MDCK-CAREx8 epithelia treated with TAT-PDZ1
or scramble peptides was collected and incubated with AdV-GFP before the mixture was
added to HeLa cells. HeLa cells are non-polarized, express high levels of CAREx7 protein
that is not susceptible to TAT-PDZ1 peptide, and are readily susceptible to adenovirus
infection (See material and methods). Conditioned media from TAT-E6 and TAT-NET1,
but not TAT-scramble exposed cells, significantly reduced GFP expression in AdV-GFP
infected HeLa cells (Figure 41). To confirm that the decreased AdV transduction was
mediated by the shed CAREx8 ECD, conditioned media from the assigned treated
conditions were cleared by immunoprecipitation using Flag antibody prior incubation
with AdV-GFP. The mixture was transferred to infect HeLa cells, and AdV transduction
was quantitated based on GFP expression. Interestingly, removal of CAREx8 ECD
restored AdV infection in HeLa cells and reversed the effect of the TAT-PDZ1 peptides
in the cell media (Figure 41). These data illustrated that TAT-PDZ1 peptides have an
indirect long-term therapeutic effect of abolishing AdV by shedding CAREx8 ECD which
acts as decoys, binding to AdV fiber-knob, to prevent AdV entry. To verify the
involvement of ADAM17 in the protective CAREx8 ECD shedding, cells were preincubated with either comp E or TIMP3 before treatment with the peptides, and
conditioned media was collected and tested for its ability to abolish AdV transduction.
Consistent with only a partial inhibition of RIP of the cytoplasmic domain by gamma-
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secretase, pre-incubation with comp E did not affect AdV transduction. By contrast, the
ADAM17 inhibitor TIMP3 completely reversed the effect of TAT-PDZ1 peptides and
restored AdV infection (Figure 41).
To further confirm the ability of CAR ECD to abolish AdV infection, CAR-FC
protein (which is a purified form of CAR ECD) was incubated with different MOI of
AdV in cell culture media before infecting HeLa cells. Whereas conditioned media from
cells treated with PBS demonstrated a dose dependent increase in AdV-GFP infection,
addition of CAR-FC to PSB-pre-incubation media could partially block the increase of
infection. Conditioned media from cells treated TAT-E6 significantly decreased AdVGFP transduction but could be partially overcome by high doses of AdV (MOI 100)
(Figure 42). Consistent with previous results, ADAM17 inhibition reversed the effect of
TAT-E6 and restored the AdV infection (Figure 42). This suggests that the shed CAREx8
ECD can act as decoy to bind AdV and protect epithelia from AdV infection.
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Figure 41. Shed CAREx8 Extracellular domain (ECD) decreases AdV infection.
MDCK-CAREx8 cells were induced with 50 ng/ml Dox O/N. Cells were treated with
vehicle, TAT-Scr, or TAT-PDZ1 peptide for 4 hrs after which the C.M. were collected,
precleared, and incubated with AdV-GFP (MOI 100) for 30 min at 37ºC. HeLa cells
were then infected with the mixture for 1 hr at 37 ºC. (A) GFP-expression in HeLa
cells infected with AdV-GFP incubated with conditioned media (C.M.) of MDCK cells
treated with either TAT-Scr or TAT-PDZ1 peptides. Notice the decrease in AdV entry

115

with C.M media from TAT-PDZ1 peptides (first row). Pre-clearing CAREx8 ECD from
C.M. by IP (second row), restored the AdV infection in HeLa cells. Pretreatment of
inducible MDCK cells with gamma-secretase inhibitor (Compound E, Comp E; third
row) did not reverse the effect of TAT-PDZ1 treatment, however, pre-treatment with
ADAM17 inhibitor (TIMP3; forth row) did reverse the effect of C.M. from TATPDZ1. (B) Quantitation of the GFP expression in HeLa cells. Quantitation was done by
Metamorph® 24 hrs post infection as described in the materials and methods, *p < 0.05
compared to PBS.
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Figure 42. CAREx8 ECD decreases AdV infection.
Stable MDCK CAREx8 cells were induced with 50 ng/ml Dox O/N prior to treatment
with vehicle, TAT-Scr, TAT-PDZ1-E6 peptide, or a combination of TAT-E6 and
ADAM17 inhibitor TIMP3, for 4 hrs. Conditioned media (C.M.) was collected,
precleared, and incubated with AdV-GFP (MOI 100) for 30 min at 37 ºC. HeLa cells
were then infected with the mixture for 1 hr at 37 ºC. (A) GFP-expression in HeLa
cells infected with AdV-GFP incubated with C.M. taken from MDCK cells or soluble
CAR EDC (CAR-Fc, 1 mg/ml). AdV-GFP infection was done at MOI 0, 25, 50, 100.
(B) Quantitation of GFP expression in HeLa cells infected in (A). Quantitation was
done by Metamorph® 24 hrs post infection as described in the materials and methods,
*p < 0.05 compared to PBS.
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TAT-PDZ1 peptides do not change epithelial integrity
I tested if TAT-PDZ1 binding peptides alter epithelial integrity by two
approaches. First, epithelial cells were seeded onto millicells and treated with a 50 µM
dose of TAT-PDZ1 peptides, TAT-scramble, or vehicle (PBS) every day over a period of
14 days. Trans-epithelial resistance (TER) measurements were taken every other day to
determine if TER reading would increase. An increase in TER indicates the formation of
tight junctions and an epithelium. Continuous treatment with PDZ1 peptides did not alter
the formation of an epithelium and epithelial integrity as showed by TER measurements
(Figure 43). The second approach involved measuring the epithelial integrity by a FITCdextran diffusion assay. FITC-dextran was added to the apical surface of the epithelia and
basolateral media collected and measured for FITC-dextran an hour later. No difference
in the permeability of FITC-Dextran 70 KD was noticed between treated and untreated
conditions (Figure 44). Similarly, no difference in the diffusion of FITC dextran 4 KD
(Figure 45A) across the epithelial cells was observed upon TAT-PDZ1 treatment as
compared to control treatment. To further confirm that this effect was due to intact tight
junctions, cells were treated with 8 mM EDTA for 10 min, followed by peptide treatment
and FITC-Dextran 4 KD diffusion assay. As expected, pretreatment with EDTA
increased FITC-Dextran 4 KD diffusion in all conditions equally (Figure 45). Taken
together, these data illustrate the safety of the TAT-PDZ1 peptide in reducing AdV
transduction without changing the epithelial integrity.
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Figure 43. TAT-PDZ1 peptides do not change Transepithelial resistance.
HAE cells were treated apically with single dose of PBS, TAT-scramble (50µM; for
4hrs) or TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. Transepithelial
resistance (TER) was taken every other day for 14 days. No change in TER was
noticeable upon treatment with TAT-PDZ1 peptides. Each condition represents the
average of 4 replicates.
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Figure 44. TAT-PDZ1 peptides do not change FITC-Dextran 70 KD permeability
across epithelia.
HAE cells were treated with single dose of PBS, TAT-scramble (50µM; for 4hrs) or
TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. FITC-Dextran 70 diffusion
across treated epithelia in the presence or absence of EDTA. There was no difference
in Dextran 70 KD diffusion among treatments. FITC-Dextran 70 was added from the
apical membrane and the diffused Dextran was collected from the basolateral media,
measured and quantified as described in the material and methods. Assay was
performed by the 14th day of peptide treatment.
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Figure 45. TAT-PDZ1 peptides do not change FITC-Dextran 4 kD permeability
across epithelia.
HAE cells were treated apically with single dose of PBS, TAT-scramble (50µM; for
4hrs) or TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. FITC-Dextran 4
diffusion across treated epithelia in the presence or absence of EDTA. There was no
difference in Dextran 4 kD diffusion among treatments. Pre-treatment with EDTA
increased Dextran 4 kD permeability in all conditions. FITC-Dextran 4 kD was added
from the apical membrane and the diffused Dextran was collected from the basolateral
media, measured and quantified as described in the material and methods. Assay was
performed at the 14th day of peptide treatment.
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Conclusions
The data presented elucidate new potential therapeutics that protect polarized
epithelia from AdV infection. The newly proposed MAGI-1 PDZ1 domain blockers
resulted in decreased CAREx8 and suppression of AdV infection. Moreover, the results
illustrated the mechanism by which the PDZ1 peptides degrade CAREx8 and decrease
AdV infection. Regulated intramembrane proteolysis (RIP) was implicated as the
mechanism involved in decreasing the level of CAREx8 and also induction of extracellular
domain (ECD) shedding of CAREx8 followed by localization of the cytoplasmic domain
to the cell nucleus. Furthermore, I described a new novel interaction mechanism between
ADAM17 and MAGI-1 PDZ2 domain. This interaction can be used to regulate ADAM17
expression and activity, which can potentially be exploited to treat many disease
conditions. A model figure of the proposed molecular mechanism of action of TATPDZ1 peptides is shown in (Figure 46). TAT-PDZ1 peptides bind the MAGI-1 PDZ1
domain, shifting more CAREx8 to interact with MAGI-1 PDZ3 domain. ADAM17, which
interacts mainly with MAGI-1 PDZ2 domain, cleaves the CAREx8 ECD. The γ- secretase
then cleaves CAREx8 from the cytoplasmic domain which is translocated to the nucleus.
CAREx8 extracellular domain is trafficked to the apical membrane where it is shed or
released to the extracellular compartment and acts as decoys that bind and neutralize
AdV.
My data showed that treatment with TAT-PDZ1 peptides but not TAT-PDZ3 (see
next section) caused cleavage of CAREx8 by ADAM17 (resides in MAGI-1 PDZ2
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domain). The exact reason for that is not currently known but one possibility is that that
distance between MAGI-1 PDZ2 and PDZ3 is shorter than that between MAGI-1 PDZ1
and PDZ2. The three dimensional orientation of each MAGI-1 PDZ domain as well as
the active site of ADAM17 is also an important factor to consider, especially with the
presence of the hinge region in the extracellular domain within ADAM17 structure.
Further experiments needed to clearly elucidate the exact mechanism. My data also
showed that ADAM17 cleavage is CAREx8 specific and did not affect the level of
CAREx7. This could be due to the different localization of the two isoforms in polarized
epithelia. Also the two isoforms differ only in the extreme C-term domain with CAREx7
contains 13 aa more. This may have caused different mode of interactions between the
two isoforms and MAGI-1.
The mechanism of protection of TAT-PDZ1 against AdV infection is shown in
another model (Figure 47). In the absence of CAREx8, the airway epithelia are resistant to
AdV entry (Figure 47A). If CAREx8 is present at the apical surface, it increases AdV
entry which can accelerate AdV replication by having more AdV per cell (Figure 47B).
Treatment with TAT-PDZ1 peptides decreased the level of CAREx8 and prevents AdV
entry thereby protecting the cells from AdV infection (Figure 47C). In addition, the shed
CAREx8 ECD generated upon TAT-PDZ1 peptides can act as decoys and decrease the
deleterious effect of AdV on the epithelium (Figure 47D).
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Figure 46. Schematic of TAT-PDZ1 peptide mediated decrease of AdV entry into
polarized epithelia.
TAT-E6 and TAT-NET1 block MAGI-1 PDZ1 shifting CAREx8 to interact with MAGI1 PDZ3 domain. ADAM17 interacts with MAGI-1 PDZ2 domain and cleaves CAREx8
ECD. The shed CAREx8 ECD interacts with and prevents incoming AdV from entry.
Gamma secretase cleaves the CAREx8 from the cytoplasmic domain region which
translocate into the nucleus.
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Figure 47. Model of protective mechanism of the TAT-PDZ1 peptides against AdV
infection in human epithelium.
(A) In the absence of CAREx8, epithelia are protected from AdV entry by the tight
junctions which separate the apical and basolateral membrane. (B) In the presence of
CAREx8 AdV enters and replicates in the epithelium, which disrupts the adherent and
the tight junctions. (C) TAT-PDZ1 peptides decrease the number of CAREx8 in the cells
which decreases the possibility of AdV entry. (D) TAT-PDZ1 peptides also induce
CAREx8 ECD shedding which acts as a decoy to protect epithelium from AdV infection.
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CHAPTER 4: Investigation of the effect and molecular mechanism of TAT-PDZ3
peptides on CAREx8 stability and Adenovirus infection
Rationale
Many of the steps that regulate the pathway through which newly synthesized
CAREx8 reaches the apical membrane remain unclear. By contrast, basolateral
localization of CAREx7 is known to require interactions with the clathrin adaptor proteins
AP-1A and AP-1B (61, 163). The discovery of MAGI-1 as a master regulator of CAREx8
protein levels prompted screening for drug therapeutics that could enhance AdV
mediated gene therapy by enhancing AdV binding and entry into epithelia. Such
therapeutics could also be used to diminish the possibility of side effects mediated by
high AdV dose required for therapeutic gene expression. The interactions between
CAREx8 and MAGI-1 are mediated by the PDZ binding domain found at the extreme Cterminus of CAREx8 and the PDZ domains within MAGI-1 that can be modulated by cell
permeable peptides.
The Rab family of small G proteins plays an important role in protein trafficking,
including defining vesicular cargo destined for apical localization (164, 165). Individual
Rabs can serve as markers for intracellular trafficking (164), which can be used to
determine the pathway responsible for CAREx8 trafficking. Such knowledge would allow
us to broaden our strategies by developing therapeutics that target CAREx8 at a specific
cellular compartment in order to enhance AdV mediated gene therapy.
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The main objective of this chapter is to test the hypothesis that cell permeable
peptides that bind the MAGI-1 PDZ3 domain can act as decoys and rescue full length
CAREx8 from MAGI-1 PDZ3 domain-mediated degradation. Increased CAREx8 at the
apical surface of polarized human epithelia can potentially enhance AdV-mediated gene
delivery in patients with genetic and acquired diseases such as cystic fibrosis, chronic
obstructive pulmonary disease (COPD), and cancer. These peptides might also behave
effectively as adjuvants to improve AdV-mediated vaccination strategies.
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Results
TAT-PDZ3 peptides bind selectively to MAGI-1 PDZ3
We have previously shown that CAREx8 interacts with both the MAGI-1 PDZ3 and PDZ1
domains, however, CAREx8 has higher affinity for PDZ3 (63). I hypothesized that
blocking the interactions between both MAGI-1 domains may be equivalent to blocking
only the PDZ3 domain. To test this hypothesis and to design blockers that are specific for
MAGI-1 PDZ3, we searched for interacting partners with the MAGI-1 PDZ3 domain,
and no other MAGI-1 domains. ESAM is a protein that is known to selectively interact
with only the MAGI-1 PDZ3 domain through its PDZ binding domain (139). The last 9
amino acids of both CAREx8 and ESAM proteins were synthesized and tagged with TAT
cell permeable peptides as described in methods and chapter 3. The selectivity of TATCAREx8-9c and TAT-ESAM toward the MAGI-1 PDZ3 domain was tested by direct
binding assay using purified peptide and Cy3-labeled MAGI-1 PDZ domains. As shown
in Figure 48, and as expected, TAT-CAREx8-9c interacts with MAGI-1 PDZ1 domain
(Kd = 23 ± 10 nM), however, it interacts with higher affinity with MAGI-PDZ3 (Kd = 4
± 2 nM). Both interactions were confirmed to be single point interactions by the double
reciprocal plot which showed a linear correlation (Figure 48). TAT-ESAM does not
interact with MAGI-PDZ1 domain (Figure 49) but it interacts with MAGI-1 PDZ3
domain (Kd = 17 ± 5 nM) (Figure 49). These data show the high affinity binding of the
TAT-PDZ3 peptides toward MAGI-1 PDZ3 domain.
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The PDZ binding domain of TAT-CAREx8-9c is required to rescue CAREx8 protein
from degradation
In order to test the specificity of TAT-CAREx8-9c toward MAGI-1 induced
CAREx8 degradation and its effect on AdV transduction, TAT-CAREx8-9c peptides with
mutated PDZ binding domain (TAT-CAREx8AA-9c) were synthesized. MDCK epithelia
were treated with either TAT-CAREx8-9c or TAT-CAREx8AA-9c. In contrast to TATCAREx8AA-9c, which did not change the protein level of CAREx8, TAT-CAREx8-9c
peptides increased CAREx8 compared to control (Figure 50). The increase in CAREx8
corresponded to an increase in AdV genome transduction (Figure 50) as well as AdV
gene expression as assessed by Ad-β-gal assay (Figure 50).
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Figure 48. TAT-CAREx8-9c binds to both MAGI-1 PDZ1 and PDZ3 domains.
Ligand binding assay between TAT-CAREx8-9c and the purified MAGI-1 PDZ1 or
PDZ-3. MAGI-1 PDZ2 domain was used as a control. TAT-CAREx8-9c peptides binds
to MAGI-1 PDZ1 (A, B; Kd= 23 ±9), and binds PDZ3 with higher affinity (C, D; Kd=
4± 2). B, D) Double reciprocal plot is linear indicating a single binding site between
the ligand and PDZ3 (D) but not PDZ1 domain (B)
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Figure 49. TAT-ESAM, a PDZ3 binding peptide, binds selectively to the MAGI-1
PDZ3 domain.
Ligand binding assay between TAT-ESAM and purified MAGI-1 PDZ1 or PDZ-3.
TAT-ESAM peptide does not bind to MAGI-1 PDZ1 (A, B) but does binds PDZ3 (C,
D; Kd= 17± 5). Double reciprocal plot shows (B) no curve indicating no binding to
PDZ1 or (D) is linear indicating a single binding site between the ligand and PDZ3.

132

Figure 50. TAT-CAREx8-9c increases apical CAREx8 and AdV transduction.
(A) Western blotting of MDCK cells treated with either TAT-CAREx8-9c or control
TAT-CAREx8AA-9c. A marked increase in CAREx8 protein level was seen in the TATCAREx8-9c treatment but not the mutated peptides. (B) QPCR of the AdV viral genome
showed a significant increase in the AdV genomic transduction after TAT-CAREx8-9c
treatment condition as compared to controls. (C) AdV-β-gal assay of MDCK epithelia
treated with TAT-CAREx8-9c or control peptides. TAT-CAREx8 -9c treatment
significantly increased the AdV-β-gal transduction compared to control peptide.
*P<0.05 compared to control or TAT-CAREx8AA-9c.
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To further confirm that the increased CAREx8 is mainly due to blocking the
MAGI-1 PDZ3 domain, MDCK epithelia were treated with TAT-ESAM which binds
solely to MAGI-1 PDZ3. Interestingly, CAREx8 protein level was markedly and similarly
increased in TAT-CAREx8-9c and TAT-ESAM treated conditions (Figure 51), indicating
that the effect is mediated by peptides binding to MAGI-1 PDZ3 domain. Consistent with
the previous data, the increase in CAREx8 corresponded to an increase in the AdV genome
entry and transduction as measured by AdV-β-gal gene expression (Figure 51). The same
experimental approach was done in primary HAE and cotton rat epithelial cells (an
animal model for AdV pathogenicity). In HAE, CAREx8 was increased in TAT-ESAM
and TAT-CAREx8-9c treated conditions. This corresponded to an increase in AdV entry
(viral genomes) and transduction (AdV-β-Gal assay) (Figure 52). Consistent with the
HAE, TAT-PDZ3 peptide treatment also increased CAREx8 protein as well as AdV-β-gal
transduction in cotton rat epithelium as compared to control peptides (Figure 53). These
data suggest that TAT-PDZ3 peptides bind MAGI-1 PDZ3 which increases apical
CAREx8 protein and promotes AdV transduction.

134

Figure 51. TAT-CAREx8-9c and TAT-ESAM increase apical CAREx8 and AdV
transduction.
(A) Polarized MDCK cells were treated with either TAT-CAREx8-9c or TAT-ESAM
and subjected to western blotting for CAREx8 protein. Actin was used to confirm equal
protein loading. (B) QPCR for Ad viral genome showed a significant increase in the
AdV genomic transduction in the TAT-CAREx8-9c and TAT-ESAM treatment
condition as compared to control (PBS). (C) AdV-β-gal assay of MDCK epithelia
treated with TAT-CAREx8-9c, TAT-ESAM, or control peptides. Both TAT-CAREx8 -9c
and TAT-ESAM treatment significantly increased the AdV-β-gal transduction
compared to control peptide. *p < 0.05 compare to control.
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Figure 52. TAT-CAREx8-9c and TAT-ESAM increase CAREx8 and AdV
transduction in human airway epithelia (HAE).
(A) Polarized cotton rats epithelial cells were treated with either TAT-CAREx8-9c or
TAT-ESAM and subjected to western blotting for CAREx8 protein. Actin was used to
confirm equal protein loading. (B) QPCR for Ad viral genome showed a significant
increase in the AdV genomic transduction in the TAT-CAREx8-9c and TAT-ESAM
treatment condition as compared to control (PBS). *p < 0.05 compare to control (PBS).
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Figure 53. TAT-CAREx8-9c and TAT-ESAM increase CAREx8 and AdV
transduction in cotton rats epithelia.
(A) Polarized cotton rats epithelial cells were treated with either TAT-CAREx8-9c or
TAT-ESAM and subjected to western blotting for CAREx8 protein. Actin was used to
confirm equal protein loading. (B) AdV-β-gal assay of MDCK epithelia treated with
TAT-CAREx8-9c, TAT-ESAM, or control peptides. Both TAT-CAREx8 -9c and TATESAM treatment significantly increased the AdV-β-gal transduction compared to
control peptide. *p < 0.05 compare to control.
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TAT-PDZ3 peptides did not change CAREx8 transcript levels
To confirm that the increase in CAREx8 was post-translational, I then tested if TAT-PDZ3
peptides increase CAREx8 by promoting CAREx8 gene expression. Treatment with TATCAREx8-9c and TAT-ESAM did not change the transcript level of CAREx8 compared to
control (Figure 54). Interestingly, pretreatment with the protein synthesis inhibitor (CHX)
partially reversed the effect of TAT-PDZ3 peptides (Figure 55). These data show that
TAT-PDZ3 peptides increase CAREx8 levels by interfering with either newly translated
protein or protein stability.
CAREx8 degrades rapidly in polarized epithelia
In order to determine the effect of TAT-PDZ3 peptides on CAREx8 protein stability, I first
determined the half-life of CAREx8 protein in the cell. Stable MDCK-Flag-CAREx8
epithelia were used and CAREx8 protein synthesis was slightly induced by a low dose of
Dox (50 ng/ml) overnight. Then, Dox-containing media was removed and replaced with
media containing the protein synthesis inhibitor CHX in order to arrest protein synthesis,
and the decrease in CAREx8 protein was tracked at different time points by Western blot.
Using the one exponential decay approach, the half-life of CAREx8 protein was estimated
to be 4.2 hrs (Figure 56). These data showed the fast turnover rate of CAREx8 protein in
cells. To determine the effect of TAT-ESAM on CAREx8 stability, I used the same
approach in the presence or absence of TAT-ESAM. Treatment with TAT-ESAM
significantly increased the half-life of CAREx8 and caused a right shift of the degradation
curve of CAREx8 (Figure 57). The experiment was not carried out long enough to clearly
determine the new half-life; however, estimation suggested that it was extended to
approximately >100 hours. Although future experiments will be used to evaluate protein
138

concentration at later time points, these data validate that TAT-ESAM increases CAREx8
stability.
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Figure 54. TAT-PDZ3 peptides do not change CAREx8 transcript levels.
RT-PCR specifically for CAREx8 transcripts after treatment with TAT-PDZ3 binding
peptides or mock treatment (PBS).
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Figure 55. TAT-CAREx8-9c and TAT-ESAM-mediated increase of apical CAREx8
is reduced by the protein synthesis inhibitor cycloheximide (CHX).
Western immunoblotting of CAREx8 in MDCK epithelia treated with either TATCAREx8 or TAT-ESAM in the presence or absence of the protein synthesis inhibitor
CHX. Both TAT-PDZ3 binding peptides increase CAREx8 protein level, the effect was
reduced upon pre-treatment with CHX.
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Figure 56. CAREx8 degrades rapidly in polarized epithelia.
MDCK cells stably expressing CAREx8 under a doxycycline-inducible promoter were
induced for different time points. By the end of each induction period, Dox was
removed and protein synthesis inhibitor (CHX) was used to stop further protein
synthesis. (A) Western immunoblotting of CAREx8 protein over time. (B) XY plot
represents the quantitation of the band intensity of CAREx8/actin from (A). The half-life
of CAREx8 was determined to be 4.2 hrs.
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Figure 57. TAT-PDZ3 peptides increase the stability of CAREx8 protein.
(A) Western immunoblotting of CAREx8 protein degradation profile over time in the
presence or absence of TAT-ESAM. Treatment with TAT-ESAM increases the
stability of CAREx8 protein. (B) XY plot represents the quantitation of the band
intensity of CAREx8/actin from (A). TAT-ESAM shifts CAREx8 protein degradation
profile and increases CAREx8 half-life.
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TAT-PDZ3 peptides increase CAREx8 protein at the apical membrane and in a
vesicular pattern within the cytoplasm
I tracked the change in level and cellular localization of CAREx8 after TAT-PDZ3
peptide treatment using ICC. Treatment with both peptides showed a dense speckled
appearance of CAREx8 localized mainly at the apical membrane (Figure 58, see xz view)
as well as within the cytoplasmic compartment of polarized epithelia (Figure 58). This
pattern of distribution is consistent with vesicular transport of CAREx8 protein to the
apical surface.
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Figure 58. TAT-PDZ3 peptides increase CAREx8 protein at the apical membrane
and in vesicular pattern within the cytoplasm.
Immunocytochemistry of polarized MDCK treated with TAT-ESAM or TAT-CAREx89c shows upregulation of the cellular CAREx8 protein level. CAREx8 is localized mainly
at the apical surface of polarized MDCK cells. After treatment with TAT-ESAM or
TAT-CAREx8-9c, CAREx8 is upregulated in a vesicular pattern within the apical surface
and the cytoplasm of treated cells. Red (CAREx8), Green (MAGI-1, a junctional
protein), Blue (nucleus, DAPI). 60x oil immersion confocal microscopy, scale bar=
10µm
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Trafficking of apical CAREx8 protein levels via Rabs
I hypothesized that CAREx8 is trafficked to the apical membrane of polarized
epithelia via a regulated endosomal pathway. Rabs, small G-proteins that belongs to the
Ras family, were used to delineate the trafficking pathway through which CAREx8 is
localized apically. The Rab families of small G proteins play an important role in protein
trafficking, including defining vesicular cargo destined for distinct localizations within a
polarized cell, including apical localization (164, 165). They serve as markers for
intracellular protein trafficking (164). I hypothesized that newly synthesized CAREx8
could be accumulated in the ER/Golgi by chilling the cells at 15-20ºC for 4 h and then
released in bulk into the endosomal pathway, and subsequent trafficking followed. My
first challenge was to determine the optimal cargo accumulation/release time in MDCK
epithelia. I used inducible MDCK-Flag-CAREx8 cells that were induced with Dox to
induce CAREx8 expression overnight. Cells were then incubated at 15-20°C for 4 hrs to
allow newly synthesized CAREx8 to accumulate in the ER and Golgi. Then cells were
incubated at 37°C at different time points for 5-20 min to allow trafficking towards the
apical membrane. Fluorescently labelled Wheat Germ Agglutinin (WGA), which binds to
sialic acid glycosylated molecules, was used as a marker for the plasma membrane as
well as trans-Golgi apparatus. At early releasing times of 5-10 min, CAREx8 was localized
mainly at the nuclear compartment, probably due to insufficient releasing time (Figure
59). However, at 10-15 min, CAREx8 could be seen leaving the ER/Golgi and entering the
cytoplasm in a vesicular pattern (Figure 59). Given the vesicle-associated distribution at
15-20 min post-release, this time point was chosen for subsequent experiments.
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Figure 59. The Golgi-ER cargo is released within 15-20 min in MDCK epithelia.
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ERGolgi cargo was accumulated by incubation at 15-20ºC for 4hrs in the presence of
protein synthesis inhibitor (CHX). To determine the optimal releasing time from the
cargo, cargo was released at different time points (A) 5 min, (B) 10 min, (C) 15 min,
and (D) 20 min followed by immunocytochemistry. Red (CAREx8), Green (Wheat
Germ Agglutinin, WGA, marker for cell membrane and late Golgi apparatus), Blue
(nucleus, DAPI). 60x oil immersion confocal microscopy, scale bar= 10µm
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CAREx8 partially co-localized with Rab4, but not Rab5
Rab4 is a marker for recycling endosomes within the apical sorting compartment
whereas Rab5 is a marker for the clathrin coated vesicles and acts as a sorting signal to
the basolateral membrane. Data showed that CAREx8 partially co-localized with Rab4 but
not with Rab5 (Figure 60). This is consistent with the apical trafficking of CAREx8 in
polarized airway epithelia and suggests that CAREx8 may alternate between the apical
membrane and recycling endosomes in polarized epithelia.
CAREx8 does not co-localize with Rab7 but partially co-localizes with Rab9
Both Rab7 and Rab9 are late endosomal markers. Rab7 goes to the lysosome to
deliver proteins destined to be degraded by the lysosomal pathway. However, Rab9
marks the vesicles that are recycled from the late endosome back to the Golgi apparatus.
Results showed that Rab7 does not co-localize with CAREx8 (Figure 61). Consistent with
the proposed mechanism of CAREx8 degradation, these data show that lysosomal
degradation is not the main pathway for CAREx8 degradation. However, there was a
partial co-localization between Rab9 and CAREx8 (Figure 62), indicating that some
CAREx8 may be recycled back to the Golgi.
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Figure 60. CAREx8 partially co-localizes with the Rab4, recycling endosomal
marker, but not Rab5.
Polarized MDCK epithelia were induced with 500 ng/ml Dox overnight. ER-Golgi
cargo was accumulated by incubation at 15-20ºC for 4hrs in the presence of CHX and
release by incubation at 37°C for 15-20 min followed by fixation and
immunocytochemistry. Red (CAREx8), Green (Rab4 or Rab5), Blue (nucleus, DAPI).
White arrow (inset) shows co-localization between CAREx8 and Rab4 shown in
yellow/orange. 60x oil immersion confocal microscopy, scale bar= 10µm
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Figure 61. CAREx8 does not co-localize with Rab7, a late endosomal marker.
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ERGolgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of
CHX and it was released by incubation at 37°C for 15-20 min. CAREx8 did not colocalize with Rab7, a late endosomal marker. This suggests that newly synthesized
CAREx8 does not go to degradation pathway. Red (CAREx8), Green (Rab7), Blue
(nucleus, DAPI). 60x oil immersion confocal microscopy, scale bar= 10µm
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Figure 62. CAREx8 partially co-localized with the Rab9, late Endosomal-Golgi
recycling marker.
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ERGolgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of
CHX and it was released by incubation at 37°C for 15-20 min. Red (CAREx8), Green
(Rab9), Blue (nucleus, DAPI). White arrow (inset) show colocalization between
CAREx8 and Rab9 shown in yellow/orange. 60x oil immersion confocal microscopy,
scale bar= 10µm
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CAREx8 almost totally co-localized with Rab11, an early endosomal marker
One of the most significant co-localizations observed was between CAREx8 and Rab11,
an early endosomal marker (Figure 63). The early endosome is an important
compartment that receives and sorts vesicles from the Golgi, recycling endosome, and
plasma membrane. Overall, these data showed that CAREx8 is trafficked through three
main pathways: 1) From the ER-Golgi to the early endosome and/or to the recycling
endosome. 2) From early endosome to late endosome or to recycling endosome. 3) From
the late endosome to back to Golgi apparatus. Future experiments will test additional later
time points and Rab inhibitors to confirm these findings.

152

Figure 63. CAREx8 almost totally co-localized with the Rab11, an early endosomal
marker.
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ERGolgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of
CHX and it was released by incubation at 37°C for 15-20 min. Localization is
consistent with ICC of CAREx8 at the sub-apical membrane of polarized epithelia. Red
(CAREx8), Green (Rab11), Blue (nucleus, DAPI). White arrows (inset) show colocalization between CAREx8 and Rab11 shown in yellow. 60x oil immersion confocal
microscopy, scale bar=10µm
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TAT-PDZ3 peptides do not change epithelial integrity
I tested if TAT-PDZ3 binding peptides alter epithelial integrity by two
approaches. First, polarized epithelial cells were treated with a dose of 50 µM of TATPDZ3 peptides, TAT-scramble, or vehicle (PBS) daily over a period of 16 days. Transepithelial resistance (TER) measurements were taken every other day. Continuous
treatment with TAT-PDZ3 peptides did not alter the transepithelial integrity as shown by
TER measurements (Figure 64). The second approach involves measuring the epithelial
integrity by FITC-dextran diffusion assay. Consistent with TER data, no difference in the
diffusion of FITC dextran 70 kD FITC-Dextran diffusion assay showed no change in the
permeability of 70 kD Dextran permeability between treated and untreated conditions
(Figure 66). Similarly, no difference in FITC Dextran 4 kD permeability was seen
between the treatment conditions after 14 days of continuous treatment (Figure 65). To
further confirm that the limited FITC-dextran diffusion effect was due to the formation
tight junctions, cells were treated with EDTA for 10 min, followed by FITC-Dextran 4
kD diffusion assay. As expected, pretreatment with EDTA increased FITC-Dextran 4 kD
diffusion in all conditions equally (Figure 66). This illustrates that TAT-PDZ3 peptides
can promote AdV transduction without altering epithelial integrity.
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Figure 64. TAT-PDZ3 peptides do not change epithelial integrity.
HAE cells were treated apically with single dose of PBS, TAT-scramble or TAT-PDZ3
peptides (50µM; for 4hrs) daily for 16 days. Transepithelial resistance (TER) was
measured every other day for 16 days. No change in TER was noticeable upon
treatment with TAT-PDZ3 peptides. Each condition represents the average of 4
replicates.
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Figure 65. TAT-PDZ3 peptides do not change epithelial integrity.
HAE cells were treated apically with a single dose of PBS, TAT-scramble (50µM; for
4hrs) or TAT-PDZ3 peptides (50µM; for 4hrs) daily for 14 days. There was no
difference in FITC-Dextran 70 kD diffusion across treated epithelia among treatments.
FITC-Dextran 70 kD was added to the apical membrane compartment and Dextran in
the basolateral media was measured and quantified as described in the material and
methods. Assay was performed after the 14th day of peptide treatment.
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Figure 66. TAT-PDZ3 peptides do not change epithelial integrity.
HAE cells were treated apically with a single dose of PBS, TAT-scramble (50µM; for
4hrs) or TAT-PDZ3 peptides (50µM; for 4hrs) daily for 14 days. (A) FITC-Dextran 4
kD diffusion across treated epithelia in the absence of EDTA. There was no difference
in Dextran 4 kD diffusion among treatments. (B) Pre-treatment with EDTA increased
Dextran 4 kD permeability in all conditions. FITC-Dextran 4 kD was added to the
apical membrane compartment and Dextran present in the basolateral media was
measured and quantified as described in the material and methods. Assay performed on
the 14th day of peptide treatment.
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Conclusions
The presented data validate new potential therapeutics that can be used to promote
AdV-mediated gene therapy. Results illustrate the mechanism by which the PDZ3
peptides promote CAREx8 protein and increase AdV infection. My data showed that
CAREx8 and AdV were increased upon TAT-PDZ3 peptide treatment in three different
cell lines, including well-differentiated primary airway epithelia. This illustrates the
reproducibility as well as the widespread application of TAT-PDZ3 peptides in
promoting AdV transduction and enhancing AdV mediated gene therapy. I also
discovered a possible mechanism of TAT-PDZ3 peptide action. The mechanism involved
increasing CAREx8 stability by reducing MAGI-1 mediated CAREx8 degradation.
However, the exact mechanism is yet to be fully elucidated. In addition, I have shown
that there was right shift in the CAREx8 degradation curve in the TAT-ESAM treated
condition; suggesting an increase in the half-life of CAREx8 protein. Further studies are
needed to determine the fold increase in CAREx8 stability upon TAT-PDZ3 peptides
treatment. Moreover, the proposed work illustrated possible trafficking pathways of
CAREx8 to the apical membrane of polarized epithelia. Although further studies are
needed, CAREx8 is suggested to be recycled between three main pathways. First, from the
ER-Golgi to the early endosome and/or to the recycling endosome. Second, from early
endosome to late endosome or to recycling endosome, and finally, from the late
endosome to back to Golgi apparatus. The significance of the data in this chapter is that
TAT-PDZ3 peptides can be exploited to enhance AdV mediated gene therapy by
overexpression of CAREx8 in order to treat a wide variety of genetic diseases and
disorders such as cystic fibrosis (Figure 67). It is also can be used to decrease the possible
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side effects by lowering the viral load given to a patient in current clinical trials where
AdV is used as vector for gene therapy.
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Figure 67. Model of enhancing AdV mediated gene therapy in cystic fibrosis (CF)
epithelium by TAT-PDZ3 peptides.
(A) In the absence of CAREx8, CF epithelia are devoid of the CFTR protein and
resistant to AdV-CFTR transduction due to low levels of apical CAREx8. (B) In the
presence of TAT-PDZ3 peptides, CAREx8 level is significantly increase which would
enhance AdV-CFTR transduction and (C) restore CFTR in the CF epithelium. CF:
cystic fibrosis, CFTR: cystic fibrosis transmembrane conductance regulator.
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CHAPTER 5: Biological evaluation of the effect of MAGI-1 TAT-PDZ peptides on
Adenovirus infection in vivo
Rationale
AdV infection is common and can be life threatening (7). Currently there are no
specific therapies to prevent or treat AdV infections and supportive care is the most
common intervention. On the other hand, AdV remains the most commonly used vector
for gene therapy (29). The objective of this chapter is the evaluation of a novel strategy to
decrease or increase airway epithelial apical CAREx8 in order to decrease or increase AdV
infection in vivo, respectively. My overall hypothesis is that decreasing apical CAREx8
will decrease AdV infection by decreasing viral entry while increasing CAREx8 in cells
can be used to enhance the efficacy of AdV mediated gene therapy.
The lung is an initial portal for infection by many wild type AdV, such as AdV5,
and is also a major target for gene therapy. Recombinant AdV-mediated gene delivery to
the airway of mice via intranasal (IN) administration has been well studied (166-169).
Low level AdV transduction in the lungs can be overcome by very high viral inoculums
(~1010 IU) which can be lethal and causes profound side effects (44).
In the previous chapters, I demonstrated that cell permeable peptides that disrupt
CAREx8 interactions with MAGI-1 were able to modulate CAREx8 levels and AdV
transduction in vitro. In this chapter, I used the novel transgenic mouse model “tdTomato” and recombinant AdV that carries cre-recombinase gene (AdV-Cre) to test the
efficacy of TAT-PDZ peptides in modulation of AdV infection in vivo.
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Results
To test the effect of the TAT-PDZ peptides on AdV infection in vivo, transgenic
mice td-Tomato (JAX stock # 007576) were used. All mouse cells have a double
fluorescent Cre reporter gene that expresses membrane-targeted tandem Tomato (tdT,
RFP variant) prior to Cre mediated excision (lox p) and membrane-targeted green
fluorescent protein (mG) after excision (170). That is, upon cre- recombinase expression,
RFP-expressing cells will be converted to GFP-expressing cells (Figure 68). The genetic
change is permanent and allows AdV transduction to be quantified based on the cell-bycell or total GFP expression lung tissue.
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Figure 68. Red-tomato mice tdT-mouse model.
All cells express a transmembrane-bound form of RFP and fluoresce red. Upon expression
of Cre re-combinase via AdV5-Cre, the tdT gene is cut out allowing transcription and
translation of transmembrane-bound eGFP. This irreversibly turns the cells from red to
green.
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TAT-PDZ1 peptides suppressed AdV entry whereas TAT-PDZ3 promoted AdV
transduction in lung tissue
Mice were anesthetized moderately by isoflurane after which they were treated
intranasally (IN) with vehicle (PBS), TAT-CAREx8-AA-9c, TAT-PDZ1 (TAT-NET1), or
TAT-PDZ3 (TAT-CAREx8-9c or TAT-ESAM) for 4 hrs. After which they were infected
IN with AdV-Cre and 48 hrs later, lung tissues were investigated for GFP expression. As
shown in Figure 69A, animals receiving no virus showed only RFP without GFP
expression. Vehicle treated mice showed uniform distribution of the number of infected
cells (shown in green) among the lung sections. Pre-treatment with TAT-PDZ1 peptides
decreased the number of infected cells in contrast to TAT-PDZ3 peptides which
increased the number of GFP infected cells. Quantitation of the number of GFP
expressing cells showed a significant increase in TAT-PDZ3 treated mice and a decrease
in TAT-PDZ1 treated mice (Figure 70). Similarly, the ratio between GFP to RFP
intensity showed a similar trend of increased and decreased infection in TAT-PDZ3 and
TAT-PDZ1 treatment, respectively.
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Figure 69. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas
PDZ3 binding peptides increase AdV5-Cre infection in vivo.
Analysis of lung cryosections from tdT mice pretreated with A) No virus, B) Control
(PBS or TAT-CAREx8-9cAA), C) PDZ1 TAT-NET1 binding peptide, or D) PDZ3
TAT-ESAM binding peptide 4 h prior to AdV5-Cre intranasal infection. 20x confocal
microscopy, Scale bar= 50µm
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Figure 70. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas
MAGI-1 PDZ3 binding peptides increase AdV5-Cre infection in vivo.
Quantitative analysis of GFP expression in lung cryosections from tdT mice with no
virus, pre-treated with control, PDZ3 TAT-ESAM peptides, or PDZ1 TAT-NET1
peptides. (A) Total GFP expressing cells counted in lung sections from different
treatment conditions. (B) Quantification of total GFP/Total RFP fluorescence in lung
section of different treated conditions by image J. There is significantly higher or lower
GFP expression in TAT-ESAM or TAT-NET1 treated mice, respectively. Data are
average of quantification from 10 sections. * P<0.05 compare to control
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TAT-PDZ1 peptides decrease viral genomes whereas TAT-PDZ3 increased viral
genomes in lung tissue of td-Tomato mice
I further confirmed the change in AdV-Cre transduction in the lungs of td-Tomato mice
by quantitation of the GFP expression. GFP mRNA was first extracted from lung sections
of treated mice, then cDNA was synthesized as described in the material and methods.
Data were normalized to control. QPCR of the synthesized DNA showed a significant
increase in GFP expression in TAT-ESAM treated mice as compared to control.
Moreover, TAT-NET1 treated mice showed significantly less GFP expression compared
to control (Figure 71). To further confirm that the formed GFP was due to change in
AdV-Cre transduction in the lung epithelia, AdV genomic copies were assessed by qPCR
of the viral genome. As expected, TAT-ESAM treated mice had increased viral genome
copies in their lung tissue compared to control while TAT-NET1 treated mice had
significantly decreased AdV genome copies in their lungs (Figure 71). These results
showed the efficacy of TAT-PDZ peptide in altering AdV transduction in vivo and
validate the use TAT-PDZ1 peptides as prophylactic treatment against AdV infection and
PDZ3 peptides as agents to promote AdV mediated gene therapy.
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Figure 71. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas
MAGI-1 PDZ3 binding peptides increase AdV5-Cre infection in vivo.
(A) RT-PCR for GFP mRNA expression after isolation of total RNA from lung tissue
of control or peptide treated mice. (B) QPCR of viral genome copies in lung tissue
from control or peptide treated mice. There is a significant increase or decrease of GFP
expression as well as viral genome copies in lung tissue from TAT-PDZ3 or TATPDZ1 treated mice, respectively. * P<0.05 compare to control
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Conclusions
In this chapter, I have performed pre-clinical evaluation of new potential
therapeutics that alters AdV infection in vivo. By using a novel transgenic td-Tomato
mouse model, TAT-PDZ binding peptides showed promising outcomes that can be used
to either promote AdV mediate gene therapy or as prophylactic treatment against AdV
infection in vivo. The advantage of using the td-Tomato mouse model is the non-invasive
and easy assessment of the efficacy of TAT-PDZ peptides in vivo. TAT-PDZ1 peptides
treatment lowered the number of AdV-Cre infected cells as well as AdV genome whereas
TAT-PDZ3 peptides increased the AdV-Cre transduction. One shortage of the in vivo
work was the relatively small N (N= 2-3). Nevertheless, more studies need to be done
with a larger “n/group” to further elucidate the safety and effectiveness of the TAT-PDZ
peptides in vivo. Future work will also focus on pathogenesis studies and gene therapy
studies to demonstrate peptide efficacy.
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CHAPTER 6: Discussion
We have shown for the first time that AdV transduction can be modulated by
targeting the apically localized CAR isoform using cell permeable peptides that interrupt
MAGI-1-CAREx8 interactions. We were able to dissect the mechanism by which MAGI-1
triggers CAREx8 degradation. TAT-PDZ1 binding peptides showed decreased CAREx8 and
AdV infection in cancer epithelial cell lined, primary human airway epithelia, and
epithelia from animal models of AdV pathogenicity (cotton rats), and in vivo. Together
this reveals a novel mechanism for prophylactic therapeutics that can reduce AdV entry
and infection of populations susceptible to AdV infection. Moreover, we used a similar
approach to develop therapeutics that would enhance AdV entry. By using TAT-PDZ3
binding peptides that block MAGI-1 PDZ3 domain, we were able to increase the apical
CAREx8 levels and enhance AdV entry in vitro and in vivo. This suggests the application
of these peptides as potential therapeutics to enhance AdV mediated gene therapy.
I showed that MAGI-1 mediates a ternary interaction between ADAM17 and
CAREx8 through its PDZ domains and that TAT-PDZ1 peptides mediate their effect by
blocking interactions with the MAGI-1 PDZ1 domain. I validated the selectivity of the
peptides to the corresponding PDZ domain by a direct binding assay. Furthermore, I
showed that MAGI-1 is a main mediator in this pathway and that silencing MAGI-1 can
reverse the effect of the TAT peptides on CAREx8. However, taking in consideration the
structural similarity between PDZ domains, as well as the fact that CAREx8 interacts with
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many PDZ domain containing proteins (47, 102-105), it is possible that these peptides
can bind and block other cellular PDZ domains. It is unknown how such off-target effects
might affect the level of CAREx8, however, I have shown the TAT-PDZ peptides do not
change epithelial cell integrity, which rules out any possible overt toxicity from such
potential off-target effects (if present) and suggests these peptides may be safe.
My data also showed that TAT-PDZ peptides indirectly targeting the nascent
translated protein of CAREx8. This was supported by the fact that the effect of the TATPDZ peptides was reversed upon inhibition the protein translation. Moreover, the
peptides effect was worn off after 24 hrs of treatment suggesting a reversible effect.
Furthermore, there was no change in the level of MAGI-1 protein upon treatment with
TAT-PDZ peptides which proved that TAT-PDZ peptides are transiently disrupting the
interaction between CAREx8 and MAGI-1 PDZ domains. Together, these data suggest a
safe and reliable therapeutic approach for regulating the susceptibility of epithelia to AdV
infection.
We and others were able to detect CAR expression at the apical membrane of
epithelial cells (45, 61, 171). It is believed that the newly discovered TAT-PDZ1 binding
peptides can abolish AdV entry by two phases. The first phase, acute phase, involves a
decrease in the apical membrane-associated CAREx8 protein level which diminished the
AdV entry due to a reduction in available receptor. This phase take place during the early
time of TAT-PDZ1 peptide treatment that causes a shift of CAREx8 binding with the
savior domain of MAGI-1, PDZ1, to the degradation domain, PDZ3. This shift causes a
transient but significant decrease in the membrane level of CAREx8 and AdV entry. The
second phase, chronic phase, is initiated by the shed CAREx8 ECD, providing long-term
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protection against AdV infection. This happened when CAREx8 bound to MAGI-1 PDZ3
domain becomes increasingly a substrate available for ADAM17. The resulting cleaved
ECD is secreted outside the cells and acts as decoy that binds AdV outside of the cell and
protects the epithelia from further AdV entry. I speculate that it may also act as a
scavenger for the nascent replicating AdV inside epithelial cells.
My data suggests that ADAM17 is responsible for CAREx8 but not CAREx7
shedding which is triggered by PDZ1 binding peptides. It is possible for ADAM10,
which has the closest homology with ADAM17, to be a candidate for CAREx8 shedding
(158). However, ADAM17 involvement in CAREx8 degradation is more likely for several
reasons. First, ADAM10 is involved in constitutive shedding (172) whereas ADAM17 is
involved in stimulated shedding (173). Second, in epithelial cells, ADAM10 has been
shown to be localized at the basolateral surface (174), in contrast, ADAM17 sequestered
mainly in the lipid rafts (175, 176), which is consistent with being localized at the apical
membrane in polarized epithelia (177). Third, the C-term domain of ADAM17 (-ETEC)
contains a class I PDZ binding motif, which enables ADAM17 to interact with PDZ
domain containing proteins (178, 179), while ADAM10 C-term domain lacks such a
sequence (-HMRR).
It is also worth noting that CAREx7 (which has identical transmembrane and extracellular
domains as CAREx8) interacts with the third PDZ domain of MAGI-1 (150). However,
the level of CAREx7 was not affected by treatment with TAT-PDZ1 peptides. There are
many possible explanations for why that happens. One of the most plausible reasons is
different sorting between the two isoforms in the polarized epithelia. In polarized airway
epithelia, CAREx8 is localized at the apical membrane whereas CAREx7 is localized at the
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basolateral membrane (45, 163). Therefore, it is predicted that ADAM17 is localized with
CAREx8 at the apical surface (175, 176), whereas ADAM10 is localized at the basolateral
membrane and if there was an interaction, ADAM10 would be responsible for CAREx7
shedding (174). This hypothesis can be tested by testing the effect of ADAM17 on
CAREx7 in non-polarized cell lines. Another possibility is that CAREx7 has 13 amino acids
more than CAREx8 at the C-term domain. This could cause a shift of the ADAM17
cleavage site within CAREx8 ECD. Such shift in the cleavage site may render CAREx7
inaccessible to cleavage by ADAM17. One possibility to test this hypothesis is by
replacing the CAREx7 cytoplasmic domain (including the PDZ binding motif) with that on
CAREx8 or alternatively by deletion some from CAREx7 to make the full length same size
as CAREx8. Finally, it is possible that each isoform is associated with a different family of
proteins due to the difference in the extreme C-term domains, which render CAREx8 but
not CAREx7 accessible for cleavage by ADAM17.
ADAM17, but not ADAM10, has a PDZ binding motif and interacts with the
third PDZ domain of another cellular PDZ-domain containing protein Dlg/SAP97 (178,
179). Interestingly, this interaction plays important role in the regulation ADAM17
activity. Disruption the ADAM17 interaction with the SAP97 PDZ domain significantly
increased epidermal growth factor receptor (EGFR) shedding by ADAM17 into the cell
media (178). If this is true, it would mean that ADAM17 activity can be regulated by
interfering with its interactions with the PDZ domain. This strategy can be used to
increase ADAM17 activity in conditions where ADAM17 is a potential therapeutic
target. My data showed that blocking the ADAM17 interaction with MAGI-1 PDZ2
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domain via TAT-PDZ2 targeted peptides reversed the degradation of CAREx8, although I
do not have evidence on how would that change ADAM17 activity.
MAGI-1 is a widely expressed scaffold protein in the body. Data from our lab has
suggested that MAGI-1 is part of the endoplasmic reticulum associated degradation
(ERAD). ERAD is a quality control mechanism that can target transmembrane proteins to
the degradation pathway. The discovery that ADAM17 interacts with MAGI-1 is a novel
finding and may link MAGI-1 mediated degradation to other associated proteins. This
new finding can potentially explain the mechanism behind degradation of other MAGI-1
interacting proteins. For example, Delta-like ligand (Dll), which plays important role in
cell communication and cell division, interacts with the fourth PDZ domain of MAGI-1
(180), and is known to undergo cleavage by ADAMs and secretases (181).
My data showed that silencing ADAM17 reversed the effect of TAT-PDZ1
peptides on CAREx8 degradation, nevertheless, many bands of CAREx8 were detected only
in the ADAM17 silencing condition. The exact reason for these bands is still unknown
but it is possible that silencing ADAM17 makes CAREx8 susceptible to post-translational
modifications such as ubiquitination. Another strong hypothesis is that ADAM17 could
be important for the proper glycosylation and folding of the full length CAREx8 (182).
The actual molecular wt of CAREx8 is 38 KD but it runs at 46 KD on a SDS-PAGE gel.
The is due to glycosylation of the extracellular domain of CAREx8. It has been shown that
glycosylation is necessary for the proper folding and for the functional effect of CAR
(182). Therefore, the non-glycosylated CAREx8 is considered misfolded and it is trapped
in the ER until it is fully glycosylated. The multiple bands of CAREx8 that appeared upon
ADAM17 silencing could be the non- or partially-glycosylated forms of CAR. If this is
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true, that would mean that ADAM17 acts as scavenger that degrades the non-functional
forms of CAREx8, which can be novel new role for the ADAM17 enzyme.
Several studies have shown that administration of “soluble CAR” ectodomain
(sCAR) is a potential antiviral strategy for both wildtype AdV and CVB infection (162,
183, 184), however, systemic administration of the sCAR is immunogenic and can
aggravate heart failure (184). Our approach is unique because it is expected to only
augment the natural pathways that release the endogenous CAR extracellular domain in
the local environment. Given the limited amount of receptor, it is predicted to be nontoxic and, since it is an endogenous pathway, is not expected be immunogenic.
There are reports that ADAM17 is responsible for cleavage of many other viral
receptors. For example, both CD163, a receptor for Porcine reproductive and respiratory
syndrome virus (PRRSV) infection, and Angiotensin Converting Enzyme 2 (ACE2) a
well-known receptor for severe acute respiratory syndrome (SARS) virus, have been
shown to undergo shedding by ADAM17, an effect that leads to decreased entry of the
corresponding virus (185, 186). Moreover, there is an argument that the efficiency of
AdV entry depends on additional stepwise interactions with co-receptors, such as
integrins (72, 73). As its names implies, (A Dis-integrins And Metalloprotease),
ADAM17 may cause shedding of the integrins from the cell surface (95, 128) and,
therefore, it is possible that this could be an additional mechanism to decreases the AdV
transduction in airway epithelia.
Although we have no preliminary data to indicate that AdV binding to CAREx8
will initiate RIP, it will be very exciting if it does. First, it is well known that AdV
infection can activate numerous cellular signaling and transcription pathways, many of
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which remain unknown but could affect viral virulence (187, 188). Second, published
evidence indicates that AdV and CVB bind CAR at the cell surface initially but that CAR
does not enter cells with the virus (75, 189, 190). Finally, shedding of the CAR
ectodomain could interfere with viral entry mechanism by endocytosis (75, 191). This
would explain a longstanding gap in the field. Insights into any of these processes could
enhance drug discovery for reduction of viral infection, and potentially even CAR-related
diseases such as dilated cardiomyopathy (183).
PDZ3 binding peptides are basically the opposite of PDZ1 binding peptides. Blocking the
interaction between MAGI-1 PDZ3 and CAREx8 led to increased CAREx8 interaction with
the savior PDZ1 domain and rescued CAREx8 from degradation. My data suggests that
this increase is associated with more CAREx8 initially co-localized with the nucleus but
then with the various endosomes within the cells. It is possible that CAREx8 is simply
escaping the MAGI-1 ERAD-like surveillance. Interestingly, MAGI-1 does not end up at
the apical surface so there must be a step of release, potentially within the Golgi sorting
steps or upon packing into endosomes. Although the pathway through the cell was not
fully characterized, blocking only the PDZ3 domain with TAT-ESAM or blocking both
PDZ1 and PDZ3 domains with TAT-CAREx8-9C appeared to be similar. Moreover, both
of these peptides behaved similarly in vivo and increased AdV-Cre transduction of tdT
mice equally. Further studies are needed to fully elucidate the mechanism of such effects.
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Future directions
In the future, we would like to test the protective effect of TAT-PDZ1 peptides in
vivo against AdV infection using animal model of pathogenicity. We would also test the
efficacy of TAT-PDZ1 peptides in protecting against the Coxsackievirus infection which
also uses CAR for binding and entry. We will also test the effectiveness of TAT-PDZ3
peptides in increase the AdV transduction and correction the cystic fibrosis in vitro and in
vivo. Even though we did not detect any toxicity in our epithelia or in vivo, developing
new peptides or other small molecule therapeutics with more specificity toward MAGI-1
PDZ1 or PDZ3 domains are more likely to have less off target effects and yield a more
specific response.
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